AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Research Library · Biotech & Healthcare

Biotech Stock Research Reports: Clinical Trials, FDA Catalysts and Cash

Dated PDF research reports on U.S.-listed biotechnology and healthcare companies. Each report follows one company through its lead programs and trial design, the regulatory path, cash, burn and runway, dilution, ownership and the catalyst map. Every report is a snapshot of the research on the date printed on its cover; the linked stock hub follows the current situation.

1 · AccessUnlock the library by watching a short ad or with a contribution.
2 · DownloadEach access includes up to 2 reports, valid for 12 hours.
3 · ReadEvery report carries its date, its sources and its disclaimer. Redistribution is prohibited.
Library access
Unlock the reports

Watch a short ad or support Merlintrader with a contribution. You decide, we don’t recommend.

OR

Subscribe free to the newsletter for a monthly pass that renews automatically while you stay subscribed.

Note: the “watch an ad” option is not available when an ad blocker or other ad-blocking tools are active. To use it, please allow ads on merlintrader.com; otherwise the Library can be opened with a contribution.

The newsletter: 1 to 3 emails a week with our latest stock hubs, research reports and key catalyst updates. Newsletter options unlock the library only after you confirm your email (check your inbox). Then: one-month pass, renewed automatically each month while you stay subscribed · 5 reports a day.

The library is open. Up to 2 downloads are included with this access.

Biotech and healthcare reports in the library

The reports cover clinical-stage and commercial companies in oncology and hematology, neurology and psychiatry, rare and genetic diseases, ophthalmology, immunology and inflammation, cardiometabolic disease, gene editing and RNA medicines, vaccines, diagnostics and medical technology. The newest reports come first. Unlock the library once with the button above, then choose up to two reports within the next 12 hours.

$LXEOResearch as of November 17, 2026PDF · 19 pages

Lexeo Therapeutics: cardiac gene therapies, FA expansion and capital

LX2020 arrhythmia data and regulatory planning, the phase 2 pivotal SUNRISE-FA 2 study, LX2006 cardiac and neurologic observations, Mantle, six-quarter finances, capital and safety risks.

$SNTIResearch as of November 17, 2026PDF · 20 pages

Senti Biosciences Holdings: the retained research business, CVRs and capital constraints

The October divestiture, retained Regulator Dial Rett and TIL research, CVR eligibility and milestones, six-quarter historical finances, post-closing funding, warrant cash-purchase rights, reverse split, listing deficiencies and control.

$MAIAResearch as of November 17, 2026PDF · 16 pages

MAIA Biotechnology: ateganosine, lung-cancer evidence and the survival trial

Ateganosine biology, THIO-101 populations and disease-control results, randomized THIO-104 survival design, historical liver safety, six-quarter financials, dilution, governance, milestones and development risks.

$ANVSResearch as of November 17, 2026PDF · 16 pages

Annovis Bio: DUET-AD evidence, funding and clinical risk

Clinical evidence and trial design; regulatory status; six-quarter financial history, cash needs, capital structure, ownership, management, upcoming milestones, risks and questions.

$LGNDResearch as of November 12, 2026PDF · 21 pages

Ligand Pharmaceuticals: Royalty Growth, XOMA and Partner Catalysts

Royalty portfolio and Captisol; XOMA acquisition, FILSPARI and OHTUVAYRE economics; QTORIN, ersodetug, AVIM and volixibat milestones; six-quarter accounts, GAAP versus adjusted earnings, cash conversion, convertible settlement, awards, ownership and risks.

$NUVBResearch as of November 12, 2026PDF · 21 pages

Nuvation Bio: IBTROZI Growth and the Safusidenib Glioma Program

IBTROZI commercial adoption and updated label; TRUST trial populations, duration and safety; safusidenib J201 and SNO, SIGMA and additional glioma studies; six-quarter finances, licensing, Sagard financing, convertible dilution, ownership and risks.

$RVMDResearch updated November 17, 2026PDF · 23 pages

Revolution Medicines research report

RASONQUE European approval, commercial execution, RASolve 301 enrollment and the RAS development portfolio. Earlier analytical chapters retain their stated dates.

$KYTXResearch updated November 12, 2026PDF · 21 pages

Kyverna: the rolling SPS BLA completed with a priority-review request and third-quarter cash of $170.572 million

Kyverna reported third-quarter 2026 results on November 12 and said it had completed the rolling Biologics License Application for miv-cel in stiff person syndrome, seeking priority review under its RMAT designation, with FDA acceptance and any PDUFA date not yet announced. Cash, cash equivalents and marketable securities were $170.572 million at September 30, with a nine-month operating cash use of $117.270 million and a $41.941 million quarterly net loss; the company forecasts runway into 2028 including amounts available from the amended Oxford facility. The report keeps BLA completion, filing acceptance and approval as distinct steps.

$INBXResearch as of November 12, 2026PDF · 20 pages

Inhibrx: Ozekibart, Ordastobart and the Financing Path

Ozekibart ChonDRAgon and BLA review, ordastobart HexAgon efficacy and safety, CRC and Ewing expansion, Oxford debt, six-quarter financial history, capital structure, ownership, governance, clinical timelines and risks.

$DNLIResearch as of November 12, 2026PDF · 22 pages

Denali: AVLAYAH Launch and the TransportVehicle Pipeline

AVLAYAH commercial launch and accelerated approval; confirmatory COMPASS evidence, zafinofusp and the TransportVehicle portfolio; six-quarter financials, Royalty Pharma economics, pre-funded warrants, ownership, governance, scenarios and risks.

$XNCRResearch as of November 12, 2026PDF · 21 pages

Xencor: XmAb819, Autoimmune Programs and Partner Royalties

XmAb819 dose selection and safety; XmAb942 XENITH-UC, plamotamab, XmAb657 and XmAb412; partner programs and obexelimab review; six-quarter financials, Alexion settlement, royalty obligations, equity exposure, governance and risks.

$IMCRResearch as of November 12, 2026PDF · 21 pages

Immunocore: KIMMTRAK, Brenetafusp and the Phase 3 Pipeline

KIMMTRAK sales and geographic mix; tebentafusp and brenetafusp randomized trials; early SITC combination cohorts; autoimmune and HIV development; six-quarter financials, rebates, convertibles, equity awards, ownership, governance and risks.

$HRMYResearch as of November 12, 2026PDF · 20 pages

Harmony Biosciences: WAKIX, BP-205 and the Patent Calendar

WAKIX commercial performance and royalty costs; pitolisant GR FDA review; BP-205 early human evidence; EPX-100 and pitolisant Phase 3 programs; patent and generic-launch exposure; dated financial statements, capital, ownership, management and risks.

$RCUSResearch as of November 12, 2026PDF · 21 pages

Arcus Biosciences: Casdatifan, PRISM-1 and the Independent Development Strategy

Casdatifan ARC-20 cohorts and Phase 3 strategy, PRISM-1 interim-analysis plan, Gilead licenses and options, Taiho regional economics and AB102; six-quarter financial history, October financing, debt, share dilution, governance and clinical risks.

$KRYSResearch as of November 12, 2026PDF · 21 pages

Krystal Biotech: VYJUVEK Growth and the Genetic-Medicine Pipeline

VYJUVEK commercial performance and international access; KB111, KB113, ocular and respiratory programs, KB707 and Jeune; six-quarter earnings, cash generation, equity awards, repurchase authorization, governance and risks.

$MIRMResearch as of November 12, 2026PDF · 21 pages

Mirum Pharmaceuticals: Commercial Growth and the 2027 Application Cycle

LIVMARLI and Bile Acid Medicines sales, ATEBRIOZ approval, brelovitug AZURE-4 results, volixibat VANTAGE and planned applications; six-quarter financial history, acquisition accounting, convertible debt, share dilution, management, scenarios and risks.

$ACADResearch as of November 17, 2026PDF · 21 pages

Acadia Pharmaceuticals: Commercial Growth, RADIANT and Patent Risk

The November 17, 2026 CTAD oral presentation of additional Phase 2 RADIANT analyses, added to NUPLAZID and DAYBUE commercial performance; remlifanserin RADIANT endpoints, study populations and safety; the 2027 clinical outlook; September 2026 financial statements, equity awards, ownership, governance, patent exposure, scenarios and risks.

$PEPGResearch updated November 13, 2026PDF · 22 pages

PEPG Stock Hub: PepGen News, DM1 Data and Clinical Development

PepGen reported 46.5% mean splicing correction in six patients treated at 10 mg/kg in FREEDOM2-DM1, with descriptive improvements in muscle-function measures. The next data window is January 2027 for FREEDOM-OLE, followed by the 12.5 mg/kg cohort in the first half of 2027. At September 30, 2026, cash, cash equivalents and marketable securities totaled $104.805 million , with company guidance into 2028. The $125 million offering priced on November 11 , 25,000,000 shares at $5.00 with closing expected on or about November 13, and the continuing U.S. partial clinical hold remain central financial and regulatory risks.

$CATXResearch as of November 9, 2026PDF · 22 pages

Perspective Therapeutics: Lead-212 Alpha Therapy, VMT-α-NET and the Phase 3 Question

The lead-212 platform and its manufacturing, VMT-α-NET in gastroenteropancreatic neuroendocrine tumours with a 39% response rate reported at NANETS, VMT01 in melanoma, the SITC data, the February 2026 financing, cash of $236.9 million at June 30 2026, the ATM, dilution, Lantheus ownership, the End-of-Phase 2 meeting guided for the first quarter of 2027, catalysts and FAQ.

$MNPRResearch updated November 12, 2026PDF · 26 pages

Monopar Therapeutics: third-quarter cash of $129.4 million, a runway to March 2028 and a rolling NDA guided to complete within weeks

Monopar reported a third-quarter 2026 net loss of $6.196 million, or $0.72 per share, and held $129.4 million of cash, equivalents and investments at September 30, with no debt and a declared runway through at least March 31, 2028. The company said on November 12 it is on track to complete the rolling New Drug Application for ALXN1840 within the next several weeks, and the 10-Q reports 6,762,620 shares and 1,843,303 pre-funded warrants outstanding at September 30. The report keeps the rolling submission, its filing review and the mechanistic dispute with Alexion separate from any approval.

$VCELResearch as of November 9, 2026PDF · 24 pages

Vericel: MACI, Epicel and NexoBrid, Growth, Guidance and Capital Returns

The three commercial products and how they are made and reimbursed, third-quarter 2026 revenue of $85.4 million and the raised full-year guidance of $344-346 million, MACI Arthro and the UK filing, the ankle MASCOT trial, the ten-year BARDA agreement for NexoBrid, cash of $235.6 million with no debt, free cash flow, the buyback, dilution, ownership, management, catalysts and FAQ.

$INTSResearch as of November 9, 2026PDF · 20 pages

Intensity Therapeutics: INT230-6, the Two INVINCIBLE Trials and the Cash Question

INT230-6 and the DfuseRx delivery technology, the first-in-human and INVINCIBLE-2 data, the Phase 3 sarcoma pause and restart, the INVINCIBLE-4 skin-reaction amendment and its 71% pathological complete response, orphan and fast-track designations, quarterly results, the $8.5 million cash position, the runway calculation, the at-the-market facility and 665,536 options and warrants, ownership, management, catalysts and FAQ.

$DTILResearch updated November 12, 2026PDF · 15 pages

Precision BioSciences: the November 5 HBV data, the priced $125 million offering and the runway into 2029

The November 5, 2026 ELIMINATE-B data showed undetectable pgRNA in 11 of 12 evaluable patients, all six at 0.4 mg/kg, with two paired biopsies showing cccDNA reductions, and FUNCTION-DMD cleared its first safety review in one child. The $125.0 million offering priced at $7.75 a share adds 16,129,041 share equivalents against $108.034 million of September cash, and on November 9 the company guided runway into the fourth quarter of 2029, counting the expected net proceeds and its at-the-market facility.

$ACRSResearch updated November 16, 2026PDF · 25 pages

Aclaris Therapeutics: the ADMIRATION miss, the ALPHA start and the ATI-9494 IND

The Phase 2 ADMIRATION study of bosakitug in atopic dermatitis did not meet its primary endpoint, the percent change in EASI at week 24, or its secondary endpoints; the company published no efficacy figures and reported robust target engagement and good tolerability. The Phase 2b ALPHA study of modzatinib in lichen planus started, with topline in the second half of 2027, the ATI-9494 IND is guided for the fourth quarter of 2026 and the ATI-052 Phase 2b in eosinophilic esophagitis for the first quarter of 2027. The report also covers the Q3 results, the October equity financing and the oral ITK pipeline; Health Score 3.00.

$XENEResearch updated November 19, 2026PDF · 18 pages

Xenon: epilepsy NDA filed, psychiatry under review

A full analysis of the azetukalner NDA in focal seizures, the published X-TOLE2 results, the KV7 class history, the September psychiatry pause and December readout, $1.15 billion of cash, 2026 financings, insiders and major holders.

$TAKResearch updated November 12, 2026PDF · 20 pages

Takeda: the ORZEYFUL U.S. launch, first-half results and the December strategy event

ORZEYFUL (oveporexton) became available in the U.S. by prescription on November 12, 2026, after its classification as a Schedule IV controlled substance, joining MIMRYLO in the U.S. market. The report sets that launch against first-half FY2026 revenue of JPY 2,407.0 billion, up 8.4% at actual exchange rates but down 1.0% at constant rates, JPY 4,575.6 billion of bonds and loans, adjusted net debt of about JPY 3,917.9 billion and a leverage ratio of 2.5 times, the zasocitinib Priority Review and the pediatric intravenous ENTYVIO application, both with FDA target action periods in the first quarter of 2027.

$ZYMEResearch updated November 16, 2026PDF · 20 pages

Zymeworks: a second $200 million buyback through 2028, after the $250 million milestone quarter

Zymeworks completed its initial 2026 repurchase program of up to $125.0 million and its board authorised a second program of up to $200.0 million through 2028, with about $140.0 million expected through 2028, a start before the end of 2026 and about 68.7 million shares outstanding on November 11. The program is funded from the balance sheet plus the $55 million Roche upfront pending HSR clearance and a possible $100 million TRELEGY ELLIPTA milestone in the first quarter of 2027. The report sets that against the third quarter of 2026: revenue of $256.5 million including the $250.0 million Jazz milestone, net income of $173.7 million, $100.5 million of cash against $413.9 million of receivables and raised 2026 guidance.

$TRAWResearch updated November 17, 2026PDF · 16 pages

Traws Pharma research report

September cash and going concern, TXM clinical-hold timing, Nasdaq deadline and financing dilution. Earlier analytical chapters retain their stated dates.

$TARAResearch updated November 8, 2026PDF · 20 pages

Protara: TARA-002, IV Choline Chloride and development economics

Research covering the bladder-cancer and lymphatic-malformation evidence for TARA-002 and the separate replacement-biology rationale behind IV Choline Chloride. It examines THRIVE-3 enrollment, response denominators, regulatory and manufacturing tasks, the September 30, 2026 accounts and the November 4, 2026 manufacturing acquisition.

$PHVSResearch updated November 15, 2026PDF · 16 pages

Pharvaris: CHAPTER-3 at ACAAI, EUR 282.7 million of cash and the 2027 filing calendar

Pharvaris summarized its ACAAI 2026 presentations on November 12, ahead of the CHAPTER-3 late-breaking oral presentation scheduled for November 14: all secondary efficacy endpoints met, 45% of deucrictibant-treated participants attack-free over 24 weeks, final CHAPTER-1 extension, RAPIDe-3 and cardiovascular safety analyses. The report sets the November 12 third-quarter results and EUR 282.7 million of cash at September 30, 2026 against the December 2 Evercore fireside chat, the first-quarter 2027 CREAATE Part 1 topline, the planned first-half 2027 extended-release NDA and the April 23, 2027 FDA target for immediate-release deucrictibant, with the November 13 close and the Health Score of 3.25.

$LBRXResearch updated November 8, 2026PDF · 19 pages

LB Pharmaceuticals: NOVA evidence, tolerability and pivotal funding

Research on LB-102 pharmacology, the randomized NOVA-1 dose comparisons and the limits of exploratory cognition findings. It separates measured weight change from cognition claims, sets the pivotal funding need against the September 30, 2026 balance sheet, and dates every trial result it cites.

$IDYAResearch updated November 17, 2026PDF · 19 pages

IDEAYA Biosciences research report

IDE849 Type C feedback and registrational plans, precision-oncology pipeline, resources and dilution. Earlier analytical chapters retain their stated dates.

$EWTXResearch updated November 5, 2026PDF · 19 pages

Edgewise: Q3 results, the Servier proceeds and the GRAND CANYON result

Dated research on Edgewise Therapeutics after its third-quarter 2026 results and Form 10-Q: $1,743.9 million of cash, cash equivalents and marketable securities at September 30, the Servier sale proceeds with $153.9 million in escrow, the contingent milestones of up to $1.1 billion after Servier’s November 3 GRAND CANYON announcement, the owned EDG-7500 and EDG-15400 programs and the planned Phase 3 start. Daily price chart through the November 4, 2026 close.

$CRDLResearch updated November 20, 2026PDF · 19 pages

Cardiol Therapeutics: CardiolRx and MAVERIC

Research on MAVERIC, ARCHER, clinical development costs and capital structure.

$AKBAResearch updated November 19, 2026PDF · 17 pages

Akebia Therapeutics, Inc.: the reimbursement reset

A full analysis of Vafseo, Auryxia, dialysis reimbursement, clinical evidence, Symbiotic financing and dilution.

$ZBIOResearch updated November 12, 2026PDF · 17 pages

Zenas BioPharma: the $200 million at-the-market reset, the Q3 base and the May 2027 obexelimab date

The November 6, 2026 prospectus supplement covers up to $200 million of common stock sold through Jefferies at market prices, after about $153.2 million had been sold and about $46.8 million remained unsold under the prior $200 million program. The report sets that capacity against $647.082 million of cash and investments at September 30, a $108.923 million third-quarter net loss, the obexelimab IgG4-related disease application under review with a May 27, 2027 target action date, and the SunStone and ZB021 readouts guided to the fourth quarter of 2026.

$VORResearch updated November 12, 2026PDF · 18 pages

Vor Biopharma: RC298 added to the RemeGen license, and the telitacicept readout ahead

On November 12, 2026 Vor announced that it had amended and restated its RemeGen license on November 11 to add RC298, a next-generation long-acting dual BAFF/APRIL inhibitor in IND-enabling development, paying $10 million upfront and issuing a pre-funded warrant for 2,300,000 shares, with up to $300 million of potential milestones and an IND in China anticipated in the first half of 2027. The report sets that against $481.6 million of cash, equivalents and marketable securities at September 30, 2026, nine-month operating cash use of $96.370 million, a runway reaffirmed into early 2029 and the global UPSTREAM MG topline expected in the first half of 2027.

$SNDXResearch updated November 20, 2026PDF · 15 pages

Syndax Pharmaceuticals: Revuforj and Niktimvo

Research on Revuforj, Niktimvo, clinical evidence and financing.

$RZLTResearch updated November 21, 2026PDF · 20 pages

Rezolute: Ersodetug and upLIFT

Rezolute enters the December 2026 readout window with two distinct hyperinsulinism programs, a completed tumor HI enrollment and a congenital HI program that missed its primary endpoint. This research note separates the two populations, tracks the fiscal Q1 FY2027 balance sheet and maps the November financing against post-quarter chronology.

$OGNResearch updated November 21, 2026PDF · 17 pages

Organon: Sun Pharma Transaction and Women’s Health

Organon’s September 30, 2026 filing shows a business still generating steady revenue and net income while carrying $8.5 billion of long-term debt. The announced Sun Pharma transaction is a signed, conditional deal, not a completed sale. This article separates reported results from transaction mechanics and examines the women’s health franchise at a high level.

$MYGNResearch updated November 9, 2026PDF · 21 pages

MYGN Stock Research: Myriad Genetics Q3 and Labcorp Prenatal Sale

Q3 results and revised guidance, the pending Labcorp prenatal transaction, operating cash flows, debt and diagnostics strategy, the November 2 network intrusion disclosed in the November 5 Form 8-K, and the executive retention stock options reported on November 9.

$MNDRResearch as of October 30, 2026PDF · 15 pages

Mobile-health Network Solutions: digital healthcare and infrastructure

The report separates the established digital-healthcare activities from clinic software, Ghana plans and proposed Malaysian data-center development. It follows conditional funding, staged commitments, regulatory history and share structure, preserving the annual financial update alongside the older interim discussion.

$GUTSResearch updated November 13, 2026PDF · 17 pages

GUTS Stock Hub: Fractyl Health News, Revita and the FDA Path

Revita met the six-month pivotal co-primary endpoint. The one-year endpoint, planned FDA submission and funding remain separate tests. The October share combination supplies no operating cash. Third-quarter results on November 12 showed $31.5 million of cash and equivalents at September 30, runway guidance into Q2 2027 and a going-concern warning, with a possible minimum-liquidity covenant breach by the end of Q1 2027 without new financing. The November 12 close was $0.8121 (-7.84% versus November 11).

$FBIOResearch updated November 20, 2026PDF · 18 pages

Fortress Biotech: Emrosi and Portfolio Value

Research on Emrosi, consolidated liquidity, royalty rights and capital allocation.

$EYPTResearch updated November 18, 2026PDF · 17 pages

EyePoint: the DURAVYU DME readout, a runway that ends first and a going-concern note

Both phase 3 wet AMD trials, LUGANO and LUCIA, missed the primary endpoint of non-inferiority in best corrected visual acuity, and the programme was concluded early with a workforce reduction of about 53% and annualized savings of about $30 million. The report covers the September quarter (revenue of $0.756 million and a net loss of $95.612 million), the $118.2 million of cash and investments at September 30, the going-concern assessment and a runway guided into late Q3 2027 against DME topline data expected early in Q4 2027, the 22,992,900 shares sold after the quarter at a $0.44 weighted average, the phase 2 VERONA results behind COMO and CAPRI, the FDA warning letter on YUTIQ manufacturing, short interest and red flags.

$CLYMResearch updated November 5, 2026PDF · 19 pages

Climb Bio Stock Research: Q3 Cash, CLYM116 and Budoprutug Updates

Q3 2026 cash and expenses, CLYM116 Phase 1 and NAVIGATE-2 updates, budoprutug PrisMN/SLE/ITP progress, share count and November 5 shelf filing.

$CLGNResearch updated November 13, 2026PDF · 25 pages

OPHI (formerly CLGN): LightSolver, rhCollagen and the financing question

CollPlant trades on Nasdaq as OPHI from November 13, 2026, formerly CLGN, after the LightSolver acquisition added photonic computing to the rhCollagen platform. The November 12 close, the last under the old symbol, was $4.64. The November 24 shareholder vote on renaming the company OptiPhi Computing, the SC26 demonstration and the dilution from the acquisition consideration frame the financing question. Merlintrader Health Score 1.60.

$CBIOResearch updated November 13, 2026PDF · 16 pages

CBIO Stock Hub: Crescent Biopharma News, Oncology Pipeline and Funding

Crescent is building an oncology portfolio around CR-001, a PD-1 × VEGF bispecific, CR-002, a PD-L1 ADC, and CR-003/SKB105, an ITGB6 ADC. Kelun holds Greater China rights to CR-001; Crescent holds CR-003 rights outside Greater China. The investment case centers on evidence quality: dose selection, tolerability, response durability and the choice of indications. A broad pipeline becomes more valuable when its studies lead to clear, disciplined development decisions.

$BTSGResearch as of October 30, 2026PDF · 15 pages

BrightSpring Health Services: care services and cash flow

The report examines BrightSpring’s pharmacy and provider-services model, demand drivers and the quality of reported growth. It follows margins, acquisitions, operating cash generation, debt and shareholder economics, with the original financial periods retained alongside the later quarterly update.

$AVTXResearch updated November 5, 2026PDF · 18 pages

Avalo Therapeutics: Q3 Results, Abdakibart and the Jefferies ATM

Q3 results, the LOTUS evidence and Phase 3 plans, funding guidance and the Jefferies sales agreement.

$AUPHResearch updated November 19, 2026PDF · 16 pages

Aurinia Pharmaceuticals: guidance raised, $486.9 million of cash and no debt

A full analysis of LUPKYNIS sales and the raised 2026 guidance, the Teva settlement and pending generic suits, aritinercept, PRESERVE and the Kezar acquisition, the March 2026 management change, third-quarter net income of $31.7 million, $131.5 million of nine-month operating cash flow, buybacks, options, insiders and holders.

$AMRXResearch updated November 12, 2026PDF · 21 pages

Amneal: the Sandoz CREXONT settlement, the 10-Q share count and the Q4 cash test

The third-quarter Form 10-Q filed on November 9, 2026 records the October 9 settlement with Sandoz that licenses generic CREXONT entry from December 21, 2037 and the dismissal of the three lawsuits on November 3, alongside 348,412,726 Class A shares outstanding at October 30, a $50.0 million revolver repayment on October 30 and the October 1 closing of a $19.8 million Rondo purchase. The report keeps Q3 revenue of $862.684 million, adjusted EBITDA of $207.029 million, $157.399 million of September cash, $3,230.747 million of gross debt and the $325-375 million operating-cash-flow forecast.

$ALNYResearch updated November 6, 2026PDF · 20 pages

Alnylam: Q3 Results, Repurchase Authorization and Commercial Leadership

Q3 results, the November repurchase authorization and commercial leadership transition.

$AGIOResearch updated November 21, 2026PDF · 21 pages

AGIO Stock Hub: Agios Pharmaceuticals News, AQVESME and Sickle Cell Review

Agios’s September results and cash uses, uptake of AQVESME in thalassemia, the FDA review of mitapivat in sickle cell disease, clinical evidence and the rare hematology pipeline. Includes ownership, scenarios and FAQ.

$ABEOResearch updated November 20, 2026PDF · 15 pages

Abeona Therapeutics: ZEVASKYN and launch execution

Research on the ZEVASKYN launch, clinical evidence, ABO-801, cash flow and capital structure.

$ABCLResearch updated November 19, 2026PDF · 17 pages

AbCellera Biologics Inc.: ABCL635 development, collaborations and September results

Research on ABCL635, the Jazz and Vertex contracts, September financial results and clinical funding.

$XERSResearch updated November 19, 2026PDF · 16 pages

Xeris Biopharma: third-quarter accounts, Recorlev growth and the raised 2026 outlook

Third-quarter 2026 revenue of $107.2 million, Recorlev at $71.5 million, net income of $11.3 million and guidance raised to $395–405 million, with cash of $131.1 million at September 30. Recorlev safety and patent disputes, XP-8121’s pivotal plan, debt settlement, secured borrowing and dilution are stated at their own dates.

$VSTMResearch updated November 18, 2026PDF · 17 pages

Verastem: an ovarian cancer launch funding a KRAS G12D bet

A full analysis of third-quarter results, the co-pack launch, VS-7375 data across pancreatic, lung and colorectal cancer, cash runway, the October offering, Oberland notes, insiders and 13G filings.

$TLXResearch updated November 21, 2026PDF · 20 pages

TLX Stock Hub: Telix Pharmaceuticals News, Cancer Imaging and the ITM Deal

Telix’s prostate imaging business, BiPASS, the Pixclara label and Zircaix review, the proposed ITM acquisition and ITM-11, June interim financial statements and the September revenue update. Includes scenarios, clinical sources, and FAQ.

$STOKResearch updated November 12, 2026PDF · 16 pages

Stoke Therapeutics: the 10-Q share count, the ATM capacity and the EMPEROR calendar

The third-quarter Form 10-Q filed on November 3, 2026 reports 65,406,268 common shares outstanding at October 30 and 64,813,537 at September 30, after about 4.6 million shares sold under the sales agreement for $146.4 million net and with nothing sold under the August 2026 $200 million prospectus. The report keeps the $358.8 million of September liquidity, the early-2028 funding horizon, the Q3 2027 EMPEROR readout and the H2 2027 U.S. NDA plan, and adds the November 17 Jefferies London investor presentation.

$SRPTResearch updated November 6, 2026PDF · 28 pages

Sarepta: ELEVIDYS, PMO review and the RNA pipeline

The October 29 research snapshot examines marketed Duchenne therapies, liver safety, ESSENCE and FDA conversion review, early RNA programs, commercial results, debt, licensed economics and litigation.

$SLSResearch updated November 17, 2026PDF · 20 pages

SELLAS Life Sciences research report

Positive Phase 3 REGAL overall-survival results, planned FDA meeting and GPS BLA, first-line SLS009 and ASH data, financial resources and dilution risks. Earlier analytical chapters retain their stated dates.

$RIGLResearch updated November 20, 2026PDF · 20 pages

Rigel: VEPPANU, commercial cash flow and R289

Separates VEPPANU launch demand from the cost of the license, using September-quarter financial statements and the clinical literature. Covers the established franchises, R289 evidence and catalysts, operating cash flow, commitments, ownership, dilution and scenarios.

$RGNXResearch updated November 19, 2026PDF · 19 pages

REGENXBIO Inc.: Pivotal retina trials, Duchenne and royalty financing

A full analysis of the pivotal retinal studies, the Duchenne filing pathway, clinical holds, September cash and royalty financing.

$REPLResearch updated November 21, 2026PDF · 19 pages

Replimune Group: TUDRIQEV launch, survival evidence and funding

Analyzes the U.S. launch, the FDA and published IGNYTE results, the randomized IGNYTE-3 survival requirement, fiscal second-quarter 2027 accounts, cash use, the Hercules covenants, dilution and ownership filings.

$PYPDResearch updated November 19, 2026PDF · 17 pages

PolyPid: the November 28 goal date, $15.5 million at September 30 and $30 million from Azurity

The third-quarter 2026 release of November 11 leaves cash, cash equivalents and short-term deposits at $15.5 million at September 30, a further $15 million Azurity milestone received after quarter end for $30 million in total, a net loss of $5.8 million for the quarter and shareholders’ equity of $3.9 million on 21,125,704 shares. The report keeps the D-PLEX100 application under priority review with a November 28, 2026 goal date, the European file validated in October and the warrant structure separate from the review outcome.

$PROKResearch updated November 21, 2026PDF · 18 pages

PROK Stock Hub: ProKidney News, PROACT 1 and the Funding Gap

The controlled PROACT 1 readout and ProKidney’s funding window frame this report. It covers the clinical evidence, the September 2026 statements, the going-concern disclosure, share structure and the new equity program.

$PDSBResearch updated November 19, 2026PDF · 19 pages

PDS Biotechnology: PDS0301 refocus, $15.2 million of cash, no debt and an $11 million milestone closing

A full analysis of the NCI colorectal data for PDS0301, the discontinued VERSATILE-003 trial, the Nant Capital private placement and its contingent closing, the repaid Yorkville note, third-quarter accounts, $15.4 million of nine-month operating cash use, an 89.9% rise in the share count, the Nasdaq deficiency, insiders and holders.

$OCSResearch updated November 16, 2026PDF · 24 pages

Oculis: the privosegtor IND clearance for acute MS relapses, PREDICT-1 and the funding structure

On November 16, 2026 the FDA accepted the investigational new drug application for privosegtor in acute relapses of multiple sclerosis, with a cross-reference to the ophthalmic IND, a strategy enrolling MS patients with optic neuritis and other relapses, a primary endpoint at three months and 3 mg/kg per day for five days. The report keeps all thirteen analytical chapters: post-DIAMOND scenarios, ordinary shares, privosegtor and ACUITY limits, PIONEER-1, licaminlimab and PREDICT-1 topline around year-end, the Accure and Novartis rights, the Q3 results, the ATM capacity and the December 8 R&D Day; Health Score 3.15.

$NVCRResearch updated November 12, 2026PDF · 16 pages

Novocure: the FDA Not Approvable Letter on Optune Mya, the Q3 base and the debt-funded transition

The November 9, 2026 Not Approvable Letter on the Optune Mya premarket approval application for brain metastases from non-small cell lung cancer is set against third-quarter revenue of $193.4 million, $463.479 million of cash and investments at September 30 and $200 million of loan principal. The report keeps the METIS evidence, the pancreatic and lung franchises, the raised 2026 revenue outlook of $736-743 million and the company’s stated next steps with the agency separate from any approval.

$NTLAResearch updated November 19, 2026PDF · 18 pages

Intellia Therapeutics, Inc.: the HAE review and separate ATTR trials

A full analysis of the lonvo-z FDA review, nex-z clinical evidence and safety, cash and OrbiMed financing.

$MNKDResearch updated November 18, 2026PDF · 17 pages

MannKind: launch spending and partner cash flow

A full analysis of Furoscix and Afrezza sales, United Therapeutics economics, launch spending, cash commitments and dilution.

$MLYSResearch updated November 5, 2026PDF · 20 pages

MLYS Stock Research: Mineralys Q3, Lorundrostat and Launch Preparations

Q3 financial results, December 22 lorundrostat FDA target, clinical evidence, launch preparation and Tanabe payment obligations.

$MDAIResearch updated November 19, 2026PDF · 25 pages

Spectral AI research report

DeepView authorization and launch, Q3 finances, Yorkville amendment and capital structure. Earlier analytical chapters retain their stated dates.

$MBOTResearch updated November 6, 2026PDF · 20 pages

Microbot Medical: LIBERTY orders, European timing and the economics of launch

The full research covers LIBERTY and its cleared use, clinical evidence, repeat orders, European timing, manufacturing, revenue, cash and historical burn, share dilution, ownership, filed litigation, scenarios, sources and FAQ. Research and regular-session market reference: November 6, 2026.

$LXRXResearch updated November 18, 2026PDF · 16 pages

Lexicon: SONATA-HCM, ZYNQUISTA and the business behind the catalysts

A full analysis of SONATA-HCM, the ZYNQUISTA application, INPEFA sales, licensing, September-quarter results, debt and dilution.

$KYMRResearch as of October 29, 2026PDF · 16 pages

Kymera: degrader evidence, pivotal plans and resources

The archive examines Kymera’s oral degrader programs, separating healthy-volunteer pharmacology from patient efficacy. It covers the KT-621 development pathway, KT-579 evidence, trial windows and September financial resources, together with spending and the risks behind management’s longer-term plans.

$IRDResearch updated November 19, 2026PDF · 21 pages

Opus Genetics: the LCA5 filing path, the BEST1 cohort and the cash runway

Cash and equivalents were $89.0 million at September 30, 2026, after a $23.0 million Oberland draw in August, and the LCA5 Phase 3 is fully enrolled with dosing in the fourth quarter of 2026 and topline at the end of 2027. The report covers the LCA5 and BEST1 designs and endpoints, the RDH12, MERTK and RHO programs, the phentolamine economics, the Oberland facility with its milestone conditions, the share and warrant reconciliation and the risks.

$SUPNResearch updated November 4, 2026PDF · 17 pages

Supernus (formerly Indivior): SUBLOCADE, the Completed Merger and Cash

Dated research on the Supernus merger completed November 2, 2026, the $8.13 special dividend, SUBLOCADE’s commercial franchise, the separate clinical study populations, cash generation, liabilities and transaction financing. Daily price chart through the November 3, 2026 close.

$INCYResearch updated November 21, 2026PDF · 20 pages

Incyte: Jakafi and the Late-Stage Pipeline

Incyte enters late 2026 as a commercial franchise in transition: Jakafi still supplies the majority of revenue but faces expected patent expirations in 2028, while Opzelura, the hematology-oncology portfolio and royalty streams are scaling fast enough to matter. A $1.25 billion Vega Therapeutics acquisition and a $1.23 billion IPR&D charge turned third-quarter GAAP results negative, yet operating cash remained positive and the balance sheet holds roughly $3.9 billion in cash and securities. The investment question is whether pipeline catalysts—CALR-directed INCA033989, latarcibart, povorcitinib and the KRAS G12D program—can convert before Jakafi erodes.

$IMUXResearch updated November 19, 2026PDF · 18 pages

Immunic, Inc.: ENSURE, progressive multiple sclerosis and funding

A full analysis of ENSURE, the progressive multiple sclerosis program, September liquidity, the February warrants and the royalty exchange.

$IMRXResearch updated November 18, 2026PDF · 16 pages

Immuneering: the path to randomized survival evidence

A full analysis of the atebimetinib trial program, pancreatic cancer competition, spending, resources and equity.

$HUMAResearch updated November 18, 2026PDF · 17 pages

Humacyte: Symvess adoption, the dialysis filing plan and funding

A full analysis of Symvess adoption and production costs, dialysis evidence and the filing plan, September-quarter financials, financing risk, litigation and Nasdaq compliance.

$GMABResearch updated November 12, 2026PDF · 17 pages

Genmab: three late-stage readouts, the nine-month base and the ASH 2026 datapoints

Petosemtamab, Rina-S and epcoritamab plus R-CHOP produced positive randomized results in October; the nine-month report of November 5 showed revenue of $3.238 billion (+22%), IFRS operating profit of $986 million, $1.860 billion of cash and $4.992 billion of borrowings, with 2026 guidance maintained. The report keeps the separate trial populations, the DARZALEX royalty base, the Merus acquisition debt and the next dated events: 22 epcoritamab abstracts at ASH 2026 on December 12-15 and a virtual R&D Update on December 16.

$ETONResearch updated November 8, 2026PDF · 14 pages

Eton: specialty sales, acquisitions and cash conversion

The report examines HEMANGEOL and IMPAVIDO within Eton’s specialty-medicine portfolio and commercial infrastructure. It follows acquisition obligations, product economics, cash conversion and development milestones, setting revenue growth against the financing and execution needed to sustain it.

$DYNResearch updated November 21, 2026PDF · 17 pages

Dyne Therapeutics: DMD Review and DM1 Evidence

Dyne Therapeutics enters late 2026 as a clinical-stage neuromuscular developer whose near-term narrative rests on a single FDA decision: the January 21, 2027 PDUFA date for z-rostudirsen in exon 51 Duchenne muscular dystrophy, filed under priority review after a May 2026 BLA submission. Behind that binary sits a second, more durable question — whether the ACHIEVE registrational expansion cohort in myotonic dystrophy type 1 can convert a six-month functional signal into an accelerated-approval package. This hub separates booked cash, trial mechanics, peer-relative context and dilution evidence so readers can judge both events on primary filings, not narrative momentum.

$DRMAResearch updated November 18, 2026PDF · 14 pages

Dermata: over 1,000 Tome orders, the runway to the first quarter of 2027 and warrant dilution

On November 17, 2026 Dermata reported additional results and before-and-after photographs from the completed cosmetic study of Tome Foundational Treatment and said it had received over 1,000 orders since the August 25 launch, without giving revenue beyond September 30 or a repeat-purchase rate. Third-quarter 2026 results report Dermata’s first product revenue, $74,000 of net sales at a gross margin of about 54%, against selling and administrative expense of $2.8 million, $5.0 million of cash at September 30 and a runway the company expects to reach only the first quarter of 2027. The analysis examines Tome demand and repeat purchases, the acne-product launch guided to the first half of 2027, the August financing, warrant conditions and resale-share supply.

$DFTXResearch updated November 19, 2026PDF · 20 pages

Definium Therapeutics, Inc.: Anxiety trials, FDA filing and financing

A full analysis of the pivotal DT120 trials, the FDA filing path, supervised care, September cash flows and potential dilution.

$CTNMResearch updated November 21, 2026PDF · 17 pages

Contineum Therapeutics: PIPE-791 and PROPEL-IPF

Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for inflammatory and fibrotic diseases. Its lead asset PIPE-791, an LPA1 receptor antagonist, is in the global Phase 2 PROPEL-IPF trial in idiopathic pulmonary fibrosis. PIPE-307, an M1 receptor inhibitor, is developed by Johnson & Johnson under a global license. Third-quarter 2026 results show $244.5 million in cash and marketable securities and a runway through mid-2029.

$CRDFResearch updated November 16, 2026PDF · 27 pages

CRDF Stock Hub: Cardiff Oncology News, the first-line Fast Track and the Phase 3

On November 16, 2026 the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab in first-line KRAS/NRAS-mutated metastatic colorectal cancer, supported by the CRDF-004 data: an objective response rate of 72.2% against 42.1% in the intent-to-treat population, with median progression-free survival not reached in the 30 mg arm against about 11 months. The report keeps the planned first-quarter 2027 Phase 3 start, still subject to financing, the cash and dilution picture, the regulatory designations and the scenarios; Health Score 2.25.

$CODXResearch updated November 10, 2026PDF · 21 pages

Co-Diagnostics: Third-quarter results, the going-concern conclusion and the funding path

Third-quarter 2026 revenue of $282,881, a negative gross profit, a $6.306 million net loss and $714,803 of cash at September 30 are set against the going-concern conclusion in the Form 10-Q filed November 10, 2026. The report covers the October J.J. Astor convertible funding, at-the-market sales and the rise to 10,512,190 shares on November 6, the CoSara tuberculosis submission to India’s CDSCO, the Flu A/B and RSV 510(k), Vector Smart installations, risks, scenarios, sources and FAQ.

$CELCResearch updated November 19, 2026PDF · 17 pages

Celcuity: the gedatolisib launch, the PIK3CA-mutant application and the June 2027 date

The quarter closed with no product revenue because no shipment reached a pharmacy or provider before September 30, 2026, and the company held $642.7 million of cash and investments against $754.0 million of convertible notes. On November 9, 2026 the FDA accepted the supplemental application in PIK3CA-mutant disease for review with a June 25, 2027 goal date. The report covers the launch metrics, VIKTORIA-1 in both cohorts, the accounts, the debt and the risks.

$CADLResearch updated November 19, 2026PDF · 18 pages

Candel Therapeutics: positive Phase 3 data, a later BLA and a larger share count

A full analysis of the Phase 3 prostate trial and the move of the BLA to mid-2027, manufacturing and biomarker work, the AURORA lung trial, linoserpaturev, $203.1 million of cash, the Trinity loan, the RTW royalty agreement, 43% share growth, warrants, options, insiders and holders.

$BHVNResearch as of November 16, 2026PDF · 16 pages

Biohaven: BHV-1530 evidence, the opakalim hold and the December 3 SK Biopharmaceuticals closing

BHV-1530’s early oncology observations are examined alongside neuroscience and immunology programs, opakalim’s partial enrollment hold, licensing agreements, quarterly cash and debt, pending contractual payments and the dilution required to fund a broad clinical portfolio. The November 16, 2026 presentation furnished on Form 8-K fixes the closing of the SK Biopharmaceuticals license on December 3, 2026, with $350 million payable at closing and $50 million one year later; the payment had not been received as of November 16.

$BCRXResearch updated November 18, 2026PDF · 14 pages

BioCryst: an ORLADEYO quarter measured against a $874 million acquisition

ORLADEYO produced $174.8 million of the $180.3 million of revenue in the September quarter, with $53.3 million of income from operations and raised guidance of $715–730 million for the year. The same nine months carry a $605.5 million net loss, because the acquisition of Astria Therapeutics cost $874.3 million and $697.8 million of acquired in-process research and development went through the income statement, leaving $988.5 million of liabilities against $591.1 million of assets. The report covers the pellet approvals and the CareMed pharmacy transition with its one-time inventory build, the $400 million Blackstone term loan and $421.7 million of royalty obligations, the navenibart programme guided to topline in the third quarter of 2027, dilution to 257.3 million shares and short interest.

$BBIOResearch updated November 20, 2026PDF · 15 pages

BridgeBio Pharma: Attruby and FDA Reviews

Research on Attruby, regulatory reviews, clinical evidence, cash flow and capital structure.

$ATYRResearch as of November 18, 2026PDF · 19 pages

aTyr Pharma: the next efzofitimod trial, financing and the reverse split

Efzofitimod, clinical and regulatory evidence, third-quarter results and capital structure.

$ARTVResearch updated November 19, 2026PDF · 22 pages

Artiva Biotherapeutics: the AlloNK discontinuation, the wind-down and $319.1 million at September 30

AlloNK development stopped on October 27, 2026 after two Grade 5 events and durability that did not meet the threshold, with a workforce reduction of about 94% and wind-down costs estimated at $27–35 million in the Form 8-K/A. The report sets that against $319.1 million of cash and investments at September 30, nine-month operating cash use of $69.8 million and a strategic-alternatives process with no stated deadline, and states that no transaction, timetable or shareholder distribution is assured.

$ARTLResearch updated November 12, 2026PDF · 13 pages

Artelo Biosciences: third-quarter cash of $4.437 million, a $1.8 million net loss and continuing going-concern doubt

Artelo reported a third-quarter 2026 net loss of $1.8 million, or $3.19 per basic and diluted share, against $3.1 million a year earlier, with cash of $4.437 million at September 30 and nine-month operating cash use of $8.849 million. The Form 10-Q filed on November 12 again discloses substantial doubt about the ability to continue as a going concern, and the at-the-market program had sold 432,062 shares for $3.0 million net through September 30, with 937,177 shares outstanding on November 11. The report keeps DREAM enrollment and the planned fourth-quarter 2026 ART26.12 repeat-dose start separate from any efficacy result.

$ARDXResearch updated November 4, 2026PDF · 32 pages

Ardelyx: Q3 Cash Conversion, IBSRELA Growth, ACCEL and Patents

All 22 analytical chapters: Q3 and nine-month earnings, cash conversion, dated Q2 financials, IBSRELA access, XPHOZAH reimbursement, ACCEL trial design and enrollment, RDX10531, patents, secured debt and covenants, equity dilution, ownership, filed litigation and risks. Daily candles, volume and SMA 50/200 on page 2 through November 3, before the Q3 release.

$AMRNResearch as of October 29, 2026PDF · 19 pages

Amarin: VASCEPA cash conversion, partner economics and EMT2 evidence

The full research covers VASCEPA and VAZKEPA, third-quarter earnings, liquidity and working-capital quality, contractual obligations, REDUCE-IT and EMT2 evidence, international partners, the Hikma settlement and remaining legal matters, ADSs and share dilution, ownership, scenarios, sources and FAQ. Research and regular-session market reference: October 29, 2026.

$ALLOResearch updated November 19, 2026PDF · 17 pages

Allogene Therapeutics, Inc.: lymphoma consolidation and autoimmune trials

A full analysis of ALPHA3 lymphoma consolidation, early autoimmune and kidney cancer data, trial funding and dilution.

$ADCTResearch updated November 11, 2026PDF · 18 pages

ADC Therapeutics: third-quarter 2026 results, the $196 million pro forma cash bridge and the November 10 resale shelf

The November 9, 2026 third quarter reported ZYNLONTA net product revenue of $21.0 million against $15.8 million a year earlier, total revenue of $21.7 million, a net loss of $25.3 million or $0.16 per share, and $189.2 million of cash at September 30 before the October 22 restructuring, with runway into 2029 on about $196 million pro forma. A November 10 Form S-3 registers the resale of 61,000,000 shares from the PIPE, not a priced offering; the report sets the LOTIS-5 benefit-risk question, the $50 million residual loan, the HCR royalties and the December ASH presentations.

$VNDAResearch updated November 12, 2026PDF · 19 pages

Vanda Pharmaceuticals: the September 30 cash test, the December 12 Quimilza date and the launch spending

The October 29 Form 10-Q puts cash and marketable securities at $140.494 million at September 30, 2026, $61.933 million of cash against $78.561 million of securities, after $109.723 million of nine-month operating cash use against $80.025 million a year earlier. The report keeps third-quarter net product sales of $69.815 million, the above-$240 million 2026 revenue outlook, the December 12 Quimilza target action date and the December 14-18 HETLIOZ hearing as separate dated tests.

$VKTXResearch updated November 15, 2026PDF · 17 pages

Viking Therapeutics: the ObesityWeek VK2735 data, the September 30 balance sheet and the road through VANQUISH

On November 15, 2026 Viking reported an exploratory 13-week VENTURE analysis presented at ObesityWeek: 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category, versus 15% on placebo, alongside VANQUISH-2 baseline characteristics; neither is a Phase 3 topline. The report covers the October 29 Form 10-Q, with $959.813 million of cash and short-term investments at September 30, 2026 against $377.342 million of nine-month operating cash use, 127,522,189 shares on the October 15 cover, the ATM and the 2032 convertible notes, VANQUISH completion expected in 2027, the oral SUNRISE program, the investor conferences of November 17 and 18 and December 2, the November 13 close and the Health Score of 2.95.

$VIRResearch updated November 13, 2026PDF · 24 pages

VIR Stock Hub: Vir Biotechnology News, ECLIPSE and Oncology

On November 8 Vir reported that the Phase 3 ECLIPSE 1 hepatitis-delta trial met its primary endpoint; it is also expanding its masked T-cell-engager oncology portfolio. Cash, cash equivalents and investments were approximately $901.3 million at September 30, before $90 million received from Gilead in October; the company still guides funding into the second half of 2028. The results were presented at AASLD on November 8 ; the company hosted an investor call on November 9 at 8:30 a.m. ET. After the close on November 12 Vir announced and then priced an underwritten public offering of 15,000,000 common shares at $10.00 , for expected gross proceeds of $150 million; closing is expected on November 16.

$URGNResearch updated November 5, 2026PDF · 17 pages

UroGen: third-quarter results, the September-quarter 10-Q, ZUSDURI growth and financing

Dated research on UroGen after the November 4, 2026 third-quarter results and Form 10-Q: ZUSDURI sales of $68.0 million, operating income of $8.3 million, the reduced JELMYTO guidance, $90.5 million of cash and securities, nine-month cash use, receivables, the Pharmakon loan and RTW revenue-linked payments, the funding statement in the 10-Q, with scenarios and the evidence that could challenge the assessment. Daily price chart through the November 4, 2026 close.

$SMMTResearch updated November 18, 2026PDF · 24 pages

Summit Therapeutics: the FDA Complete Response Letter, the ivonescimab program and the AstraZeneca funding

On November 15, 2026 Summit announced an FDA Complete Response Letter for ivonescimab plus chemotherapy in EGFR-mutated lung cancer after EGFR TKI therapy: according to the company, overall survival was not statistically significant, while progression-free survival was met. The report covers the original and later HARMONi analyses, the trials that continue, including HARMONi-3, cash of $629.8 million at September 30 plus the $2.0 billion AstraZeneca investment, conversion and resale registration, dilution, governance, a dated price chart and the Health Score of 2.75.

$RLAYResearch updated November 21, 2026PDF · 17 pages

Relay Therapeutics: Zovegalisib and Precision Medicine

Relay Therapeutics is a clinical-stage precision oncology company whose value now hinges on one mutant-selective PI3Kα inhibitor, zovegalisib, advancing through a pivotal second-line breast cancer trial while a separate vascular-anomalies program generates early data. The balance sheet carries roughly $849 million into a management runway projected into 2029, a considerable cushion that nonetheless confronts a rising quarterly spend and a share count swollen by 2026 financings. This hub separates reported results from prospective milestones, and distinguishes randomized evidence from single-arm and preclinical work, so readers can judge what is booked, what is planned, and what remains unproven.

$RAPPResearch updated November 21, 2026PDF · 20 pages

RAPP Stock Hub: Rapport Therapeutics News, Focal Epilepsy and Bipolar Mania

RAP-219 in focal epilepsy and bipolar mania, the pivotal FOCUS trials, September financial statements, October equity and convertible notes, regional licensing, scenarios and FAQ.

$QUREResearch updated November 19, 2026PDF · 19 pages

uniQure: AMT-130 under Priority Review with a May 1, 2027 target date

A full analysis of the AMT-130 data at 36 and 48 months and the external control, the accepted BLA, the advisory committee and confirmatory study, AMT-260 and AMT-191, the HEMGENIX royalty financing, $768.4 million of cash and investments, the Hercules loan, 12.4% share growth, insiders, holders and the class action.

$PRMEResearch updated November 13, 2026PDF · 17 pages

PRME Stock Hub: Prime Medicine News, Prime Editing and Liver Programs

On November 12, 2026, Prime Medicine closed its underwritten public offering of 41,071,428 shares at $3.50 , including the full exercise of the underwriters’ option for 5,357,142 shares, for gross proceeds of about $143.7 million and net proceeds of about $134.7 million. The same day it reported third-quarter results: $61.2 million of cash, cash equivalents and short-term investments at September 30, excluding $13.7 million of restricted cash, and pro forma resources of about $209.5 million including the net proceeds and restricted cash. It guides funding through 2027, while its Form 10-Q still reports substantial doubt about going concern. Prime Medicine enters its next clinical stage with FDA clearance for both liver programs, a human proof of concept in a different disease, and a cash balance that makes financing part of the investment story. The September 24, 2026 announcement cleared PM647 for a US trial; the July 23 announcement did the same for PM577a. Initial liver data are company targets for 2027, while the August 6 update targeted a PM359 biologics application in the first half of 2027. These are distinct milestones with different requirements. Trial permission is not human efficacy, and a planned application is not regulatory acceptance.

$PGENResearch updated November 19, 2026PDF · 19 pages

Precigen: the PAPZIMEOS ramp, the receivables and the European review

PAPZIMEOS net revenue was $72.9 million in the September 2026 quarter, up 37% from $53.1 million in June and $151 million since the fourth-quarter 2025 launch, and the company reported net income of $35.8 million. The report covers the commercial ramp, the 127-day receivables and the wholesaler concentration, the $100 million term loan and its covenants, the insurance coverage and J-code, the Kirk stake, dilution and the risks.

$ORICResearch updated November 21, 2026PDF · 17 pages

ORIC Pharmaceuticals: Enozertinib and Rinzimetostat

ORIC Pharmaceuticals is a clinical-stage oncology company developing two late-stage assets against resistance mechanisms in prostate and lung cancer. Rinzimetostat, a PRC2 inhibitor, entered a global Phase 3 in metastatic castration-resistant prostate cancer in November 2026. Enozertinib, an EGFR inhibitor, is being prepared for a first-line Phase 3 in EGFR atypical non-small cell lung cancer with initiation expected in the first half of 2027. The company reported no product revenue for the quarter ended September 30, 2026.

$NVOResearch updated November 18, 2026PDF · 18 pages

Novo Nordisk: GLP-1 volume against price

A full analysis of nine-month results, U.S. and international pricing, the 2027 list-price reset, CagriSema and zenagamtide evidence, impairments, cash flow and buybacks.

$MTVAResearch updated November 18, 2026PDF · 13 pages

MetaVia: the extended Part 3A visit completed and the DA-1726 evidence

On November 17, 2026 MetaVia said the last patient had completed the final study visit of Part 3A, whose treatment period the company extended from 16 to 24 weeks with an additional eight weeks at 48 mg weekly; full Part 3A and Part 3B data remain guided to the first quarter of 2027. The preclinical DA-1726 ObesityWeek results released November 16 are distinguished from the November human Part 3B interim analysis; Q3 cash, funding risk, vanoglipel, future trial windows, dilution and Health Score 2.15.

$LGVNResearch updated November 21, 2026PDF · 19 pages

Longeveron: Laromestrocel and Strategic Review

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing laromestrocel (Lomecel-B), an investigational allogeneic cellular therapy, across rare pediatric cardiac conditions and aging-related frailty. The company reported third quarter 2026 results on November 12, 2026, disclosed that the ELPIS II Phase 2b trial in hypoplastic left heart syndrome (HLHS) missed its primary endpoint while showing a statistically significant secondary MACE result, and confirmed a strategic review process with Lucid Capital Markets retained as financial advisor. This article examines the company-specific scenarios, business model, and the two lead development programs using primary filings and peer-reviewed literature.

$KPTIResearch updated November 17, 2026PDF · 19 pages

Karyopharm Therapeutics research report

FDA acceptance of the myelofibrosis sNDA and June 2027 PDUFA, OTC KPTIQ, Chapter 11 milestones and the proposed cancellation of existing equity. Earlier analytical chapters retain their stated dates.

$KNSAResearch updated November 12, 2026PDF · 23 pages

Kiniksa Pharmaceuticals: $568.8 million of cash, the November 16 fireside chat and 78.6 million shares

The September 30, 2026 Form 10-Q reports 78,571,705 ordinary shares outstanding at October 23, $568.8 million of cash, cash equivalents and short-term investments with no debt, $144.9 million of operating cash flow in the first nine months and third-quarter net income of $47.3 million. Management takes part in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16 at 11:00 a.m. GMT, and PASTORALE Phase 3 data remain guided to the second half of 2027.

$IOVAResearch updated November 13, 2026PDF · 31 pages

IOVA Stock Hub: Iovance News, Amtagvi and Clinical Data

On November 5 Iovance reported record third-quarter product revenue of $121.5 million , up about 80% in a year, a net loss of $22.3 million and 2026 revenue guidance of $410–420 million reaffirmed as on track, with about $382 million of cash, investments and restricted cash at September 30 that the company expects to fund operations well into 2029. The shares closed at $14.81 on October 28 and at $8.04 on November 6, after the October 29 lung-cancer update showed a 24.6% response rate in 69 patients and 59.1% in a retrospective biomarker subgroup of 22. The registrational question rests on POSITILITY, a prospective biomarker-enriched cohort with a target of 80 patients whose enrollment the company said would begin in November.

$ICUResearch updated November 12, 2026PDF · 25 pages

SeaStar Medical: third-quarter cash, 251 of 339 adults enrolled and the SAVE registry closed out

Third-quarter 2026 net revenue was $0.635 million against $0.183 million a year earlier, with a net loss of $4.529 million and cash of $3.989 million at September 30 before the roughly $3.3 million of gross October warrant proceeds. SeaStar reported 251 of 339 planned NEUTRALIZE-AKI patients enrolled, with completion now expected by mid-2027 rather than the earlier year-end 2026 or first-quarter 2027 window, and has submitted the first module of a modular premarket approval application. On November 3 the FDA determined that the pediatric SAVE registry had fulfilled the post-approval study requirements of the QUELIMMUNE Humanitarian Device Exemption. The October 30 Form S-3 is a shelf registration for resale, not a priced offering.

$HIMSResearch updated November 18, 2026PDF · 19 pages

Hims & Hers: peptides, cash conversion and acquisition payments

A full analysis of third-quarter results, gross margin, free cash flow, Eucalyptus deferred payments, convertible notes, dilution and the FTC lawsuit.

$HELPResearch updated November 17, 2026PDF · 23 pages

Helus Pharma research report

APPROACH Phase 3 topline efficacy and treatment-related serious adverse events, financial resources, EMBRACE, HLP004 and financing risks. Earlier analytical chapters retain their stated dates.

$CRSPResearch updated November 20, 2026PDF · 16 pages

CRISPR Therapeutics: CASGEVY and Clinical Pipeline

Research on CASGEVY, clinical evidence, cash flow and capital structure.

$CMPSResearch updated November 19, 2026PDF · 18 pages

Compass Pathways plc: COMP360, regulatory review and September finances

Research on COMP360 clinical evidence, FDA review, access, cash and share capital.

$BEAMResearch updated November 21, 2026PDF · 22 pages

BEAM Stock Hub: Beam Therapeutics News, Risto-cel and Cash Runway

The BEACON pivotal topline and risto-cel filing window, the global BEAM-302 cohort, September cash and operating results, conditional Sixth Street debt, and dilution. Includes clinical evidence, scenarios, and FAQ.

$BCTXResearch updated November 18, 2026PDF · 15 pages

BriaCell: the Bria-ABC interim analysis, a slipped timeline and a going-concern balance sheet

The pivotal phase 3 study of Bria-IMT plus a checkpoint inhibitor randomizes 177 patients against 177 on physician’s choice, with overall survival as the endpoint and a first interim analysis at 144 events; a hazard ratio of 0.6 or better supports a filing. The report covers the December 2025 guidance to a first-half 2026 topline and the October 2026 annual report that still described the study as progressing toward that analysis, the fiscal 2026 results with a net loss of $34.904 million and $20.540 million of cash and investments at July 31, the going-concern statement, the $34.7 million of gross financings and the two share consolidations, BriaPro at about 78% ownership, the listed warrant series, short interest and the red flags.

$AVXLResearch updated November 12, 2026PDF · 30 pages

Anavex Life Sciences: blarcamesine, the Rett study and the European withdrawal

Blarcamesine targets Alzheimer’s disease, Rett syndrome and Fragile X. After the withdrawal of the European application, the report follows the U.S. programmes, the cash and financing position, the governance questions and the dated milestones, keeping company statements separate from the clinical evidence.

$ARQTResearch updated November 21, 2026PDF · 18 pages

Arcutis Biotherapeutics: ZORYVE and Clinical Expansion

Arcutis has moved from launch-stage losses to a profitable, cash-generating dermatology franchise built on one molecule, roflumilast, sold as several creams and a foam. The questions that matter now are whether gross-to-net, access and prescriber breadth keep demand compounding while commercial spending runs ahead of sales, whether the new at-the-market capacity is ever used, and whether vitiligo, infant atopic dermatitis and hidradenitis suppurativa extend the label or merely extend the cost base.

$ANNXResearch updated November 21, 2026PDF · 17 pages

Annexon: ARCHER II and GBS Filing

Annexon enters the final weeks of 2026 with two registrational programs facing near-term, independently verifiable tests: the ARCHER II Month 15 Data Monitoring Committee assessment in geographic atrophy and a U.S. tanruprubart BLA submission in Guillain-Barré syndrome. The $213.4 million September 30 cash and investment balance, a $50 million Oxford draw and up to $150 million of milestone- or lender-conditioned facility capacity frame the runway. The investment question is whether functional benefit replicates under controlled conditions and whether the evidence package satisfies regulators, not whether the complement mechanism is elegant.

$ZURAResearch updated November 21, 2026PDF · 20 pages

Zura Bio: TibuSHIELD and Tibulizumab Funding

Zura Bio entered the second half of November 2026 with a clean division between what has failed and what remains untested. Tibulizumab missed every efficacy endpoint in hidradenitis suppurativa, and the company ended that program, yet a $187.7 million cash balance is guided to cover operations through at least the end of 2028. Systemic sclerosis is the next binary readout, polymyalgia rheumatica is a planned trial, and the case now rests on whether a distinct disease can validate dual IL-17 and BAFF blockade.

$WORXResearch as of October 27, 2026PDF · 18 pages

SCWorx: data operations, Nasdaq and financing

The archive examines SCWorx’s healthcare-data business and the economics of new software workflows. It sets revenue, losses and liquidity against Nasdaq monitoring, warrant exercises and resale registration, explaining dilution and the limits of interpreting registration capacity as company cash.

$VTVTResearch updated November 8, 2026PDF · 18 pages

vTv Therapeutics: cadisegliatin evidence, CATT1 and per-share economics

Analysis of cadisegliatin’s mechanism, the earlier randomized and insulin-withdrawal studies, the CATT1 design and its distinct hybrid closed-loop pilot. It examines licensing accounting, normalized historical cash use, pre-funded warrants, territorial rights and the difference between enrollment and pivotal efficacy evidence.

$VERAResearch updated November 19, 2026PDF · 17 pages

Vera Therapeutics, Inc.: Trutakna launch, IgA nephropathy and September results

Research on Trutakna, ORIGIN 3, Vera’s first product sales, cash use and financing.

$SRRKResearch updated November 20, 2026PDF · 19 pages

Scholar Rock: early ISEMBYLD sales, patient access and fracture surveillance

From initial specialty-network shipments to covered repeat infusions: the September accounts, SAPPHIRE and the FDA label, the European and Japanese applications, and how the priority review voucher and Blue Owl facility shape financing.

$SENSResearch updated November 17, 2026PDF · 18 pages

Senseonics research report

iLet–Eversense 365 commercial launch, Gemini, Q3 finances and financing risks. Earlier analytical chapters retain their stated dates.

$PTGXResearch updated November 11, 2026PDF · 14 pages

Protagonist Therapeutics: third-quarter 2026 results, the October Takeda collection and the royalty base

The November 5, 2026 third quarter brought $274.410 million of licence and collaboration revenue and a $220.015 million net income, of which about $266.6 million came from the $275 million Takeda payments collected in cash in October, after a September 30 balance sheet that showed $834.621 million of cash and securities. The report sets the MIMRYLO and ICOTYDE royalty tiers, the September repurchase authorization with 40,560 shares bought for $5.8 million, the early-2027 PN-881 Phase 2b start against $146.888 million of nine-month operating cash inflow, scenarios, sources and FAQ.

$PRAXResearch updated November 21, 2026PDF · 19 pages

Praxis Precision Medicines: Relutrigine and Ulixacaltamide

Praxis Precision Medicines enters late 2026 as a clinical-stage CNS company with two new drug applications under FDA review and a third late-stage asset still generating data. Relutrigine carries a December 27, 2026 target action date in SCN2A and SCN8A developmental and epileptic encephalopathies; ulixacaltamide carries January 29, 2027 in essential tremor. Neither is an approval. The investment question is whether two separate evidence packages, a broad-DEE readout and roughly $1.29 billion of September 30 resources can convert into durable commercial franchises before spending and dilution reshape the per-share economics.

$ORKAResearch updated November 21, 2026PDF · 18 pages

Oruka Therapeutics: EVERLAST and Long-Acting Antibodies

Oruka Therapeutics is a clinical-stage biotechnology company developing half-life extended antibody therapeutics for chronic skin disease. Its lead asset, ORKA-001, is an IL-23p19 monoclonal antibody engineered for extended dosing intervals. A second program, ORKA-002, targets IL-17A/F with a similar half-life extension approach. The company has no approved products and no product revenue. Its public equity trades on Nasdaq under the ticker ORKA. The investment case rests on clinical readouts from two Phase 2 programs, the timing of a Phase 3 transition for ORKA-001, and the company’s ability to fund operations through those milestones. This article examines the documented evidence from the EVERLAST program, the ORCA-SURGE program, and the company’s reported financial position as of the latest quarterly filing.

$NYXHResearch updated November 18, 2026PDF · 16 pages

Nyxoah: accelerating U.S. growth, a lowered guidance, a costly runway

A full analysis of the Genio U.S. launch metrics, the guidance cut, ACCCESS and the CCC supplement, the patent fight with Inspire, third-quarter accounts, debt, the convertible bond and dilution.

$NKTRResearch updated November 19, 2026PDF · 19 pages

Nektar Therapeutics: atopic dermatitis, alopecia and financing

A full analysis of pivotal atopic dermatitis and alopecia trials, the evidence behind them, royalty obligations, cash use and financing.

$NAUTResearch updated November 19, 2026PDF · 17 pages

Nautilus Biotechnology: Voyager shipments planned for mid-2027, broadscale deferred

A full analysis of Iterative Mapping and the tau study in Nature Methods, the realigned proteoform roadmap, the deferred broadscale assay, early access and ARPA-H funding, $114.3 million of cash and investments with no debt, the unused $125.0 million at-the-market program, options, insiders and holders.

$MRNAResearch updated November 19, 2026PDF · 17 pages

Moderna: the September quarter, the COVID franchise and the intismeran melanoma filing

Revenue was $1.313 billion in the September 2026 quarter, and the nine-month net loss of $1,963 million includes an $890 million settlement charge. The report covers the COVID franchise and the 2026–2027 strain update, mFLUSIVA and the combination vaccine, the intismeran autogene filing in resected melanoma and the other INTerpath programs, the $3.0 billion of convertible notes issued on September 1, the amended Ares facility, the November 12 Analyst Day cost framework and the 2027 tests.

$LFWDResearch updated November 21, 2026PDF · 21 pages

Lifeward: Rehabilitation Sales and Funding

Lifeward enters late 2026 as two businesses sharing one balance sheet: a rehabilitation device portfolio where AlterG is growing and ReWalk is being rebuilt around channel partners, and a biomedical pipeline that arrived with the March Oratech transaction and now consumes a material share of research spending. The investment question is not whether exoskeleton technology works in controlled studies; it is whether distribution, reimbursement and cash conversion can fund a cost base that has outgrown gross profit. Filed results for the quarter ended September 30, 2026, describe a company with $4.5 million of unrestricted cash, substantial doubt about going concern, and a controlling shareholder that is also its lender.

$LEGNResearch updated November 19, 2026PDF · 17 pages

Legend Biotech Corporation: CARVYKTI, collaboration economics and LB2501

Research on CARVYKTI’s commercial and clinical evidence, LB2501, September earnings, partner settlements, funding and ownership.

$KRROResearch as of November 5, 2026PDF · 16 pages

Korro Bio: third-quarter accounts, the ANCHOR trial and the Novo termination

Third-quarter 2026 research and development expense of $12.1 million, a net loss of $17.5 million and $124.8 million of liquidity at September 30, with a guided runway into the second half of 2028. KRRO-121 in urea cycle disorders, KRRO-111 in AATD, the KRRO-110 reset and the November 3 termination of the Novo Nordisk collaboration are stated at their own dates.

$KODResearch updated November 18, 2026PDF · 16 pages

Kodiak: the KSI-101 December readout, the Zenkuda filing and a going-concern balance sheet

Zenkuda and tabirafusp-ted met their primary endpoints in the pivotal DAYBREAK study on September 28, 2026, and a multi-indication Zenkuda application is planned for the fourth quarter. The report covers the first 300-patient PEAK cohort of KSI-101, guided to topline in December 2026, and the second cohort of 600 patients across PEAK and PINNACLE in the second quarter of 2027; the September quarter, with a net loss of $66.2 million and $88.7 million of cash at September 30; the going-concern assessment and the $68.9 million raised net under a $350 million at-the-market facility after the quarter; the 22.3 million options at a $36.09 average; manufacturing at URSUS; short interest; and the red flags.

$IBRXResearch updated November 11, 2026PDF · 50 pages

ImmunityBio: third-quarter 2026 results, the QUILT-2.005 primary endpoint and the BCG-naïve filing

The November 9, 2026 third quarter brought net product revenue of $48.7 million, up 53% year over year but below the $50.7 million of the second quarter, and $143.6 million in the first nine months. The same day ImmunityBio reported that the randomized QUILT-2.005 trial of 370 BCG-naïve patients met its primary endpoint without disclosing response rates, and Israel approved ANKTIVA plus BCG. The report sets the October 14 label expansion, $334.3 million of cash and securities at September 30, the going-concern language, the $480.0 million related-party note and the dated catalysts against a 1.06 billion share count and 160.5 million potential shares.

$GERNResearch updated November 5, 2026PDF · 50 pages

Geron: Q3 RYTELO Profitability and the Business After IMpactMF

Q3 results and 10-Q cash flows, debt and share counts, RYTELO demand and the ASH poster program.

$DNTHResearch updated November 5, 2026PDF · 22 pages

DNTH Stock Research: Claseprubart, MoMeNtum and Q3 Financials

Q3 financials, claseprubart and MoMeNtum, CAPTIVATE timing, the DNTH212 and DNTH312 pipeline, and dilution.

$CORTResearch updated November 20, 2026PDF · 18 pages

Corcept Therapeutics: Lifyorli and Relacorilant

Research on Lifyorli launch, quarterly earnings, clinical evidence and regulatory calendar.

$ARWRResearch updated November 19, 2026PDF · 21 pages

Arrowhead Pharmaceuticals: REDEMPLO, the sHTG filing and a heavier balance sheet

A full analysis of the SHASTA-3 and SHASTA-4 results and the priority review in severe hypertriglyceridemia, the first REDEMPLO launch year, the pipeline and partner revenue, a $724.2 million fiscal 2026 loss, $1.19 billion of cash, the new term loan and convertible notes, dilution, insiders, holders and the Ionis lawsuit.

$AQSTResearch updated November 18, 2026PDF · 20 pages

Aquestive: the Anaphylm Class 2 review, the September cash base and two approval-contingent contracts

Anaphylm carries an accepted Class 2 resubmission with a March 16, 2027 FDA goal date, and approval would release $75 million from RTW and a $20 million Oaktree tranche, with $25 million more after a sales milestone and $50 million only with lender consent. The report covers the September quarter, with revenue of $7.557 million, a net loss of $16.496 million and $90.349 million of cash at September 30; the January 2026 complete response letter on human factors and the pouch and labeling changes; the LIBERVANT license to Eton, with action goals on March 23 and March 29, 2027; the royalty obligations and the KYNMOBI liability; dilution, with 2,805,271 warrants and about $73 million of at-the-market capacity; the 29.3 million shares short at the October 30 settlement; and the red flags.

$ANLResearch as of October 27, 2026PDF · 14 pages

Adlai Nortye: cancer pipeline and financing

The report examines Adlai Nortye’s oncology platform, the evidence for its clinical candidates and the limits of extrapolating early or combination data. It follows development milestones, licensing commitments, financial resources and the dilution and execution risks behind the pipeline.

$TVTXResearch updated November 20, 2026PDF · 18 pages

Travere Therapeutics: FILSPARI and HARMONY

Research on FILSPARI, HARMONY, licensing economics and convertible debt.

$RXRXResearch updated November 18, 2026PDF · 14 pages

Recursion: Q3 Funding, REC-4881 and Clinical Evidence

All 18 original chapters: Q3 and nine-month finances, TUPELO and DAHLIA, pipeline priorities, partnerships, data economics, dilution, leadership, risks and historical comparisons. Daily price chart through November 3, after the Q3 release.

$OTLKResearch as of October 26, 2026PDF · 26 pages

Outlook Therapeutics: LYTENAVA launch, cash runway and capital risks

The October 26 research snapshot examines the FDA and clinical history, U.S. launch and pricing, reimbursement, cash, Atlas obligations, European commercialization, dilution, ownership, listing and legal risks.

$OMERResearch updated November 17, 2026PDF · 37 pages

Omeros research report

Q3 YARTEMLEA revenue and cash flow, financial resources, 340B outpatient reimbursement and study plans. Earlier analytical chapters retain their stated dates.

$OCULResearch updated November 11, 2026PDF · 19 pages

Ocular Therapeutix: third-quarter 2026 results, the Q4 NDA plan and the SOL-R endpoint move

The November 9, 2026 third quarter brought net revenue of $12.9 million, a net loss of $94.8 million, or $(0.42) per share, and cash and cash equivalents of $530.6 million at September 30, guided into 2028. The AXPAXLI NDA remains on track for the fourth quarter under the 505(b)(2) pathway after the interim SOL-R Week 52 safety analysis, while the SOL-R primary endpoint moved to Week 40 and full topline stays in the first quarter of 2028. The report covers SOL-1 and its single-injection comparator, repeat dosing, DEXTENZA revenue, the $82.474 million Barings debt, 220.0 million shares and the November 6 board change.

$OCGNResearch updated November 12, 2026PDF · 27 pages

Ocugen: the Celairis licence for OCU400 in Asia-Pacific, the December 22 vote and the cash

The November 10, 2026 exclusive licence to Celairis Therapeutics covers OCU400 for retinitis pigmentosa in Australia, New Zealand, Singapore, Malaysia, Thailand, the Philippines, Vietnam and Indonesia, for up to $7.1 million in aggregate fees and one approval milestone, before a high-single-digit royalty and half of gross profits. The report keeps that agreement separate from the December 22 vote on authorised shares, the $130 million of convertible notes, $84.6 million of cash at September 30 and the going-concern conclusion.

$NVAXResearch updated November 6, 2026PDF · 30 pages

Novavax: Q3 Results, Sanofi Milestones and Seasonal Vaccines

Q3 results and 2026 financial outlook, the earned Sanofi milestone, the Form 10-Q cash flows, convertible notes and share count, seasonal vaccines and partner economics.

$NRXPResearch updated November 17, 2026PDF · 24 pages

NRx Pharmaceuticals research report

Third-quarter results, ketamine approval and first order, shipments, Yale collaboration, NRX-100 and NRX-200 development, DARPA and financing risks. Earlier analytical chapters retain their stated dates.

$MEDSResearch updated November 18, 2026PDF · 16 pages

DataMeds AI: a small pharmacy and lab against a large overhang

A full analysis of third-quarter results, revenue by line, cash and debt, the May 2026 notes, warrants and at-the-market program, Helomics, DiaGen, peptides and the HMO memorandum.

$MEDPResearch as of October 26, 2026PDF · 15 pages

Medpace: award quality, backlog conversion and cash discipline

Archived analysis of the full-service clinical-research model and the path from net awards to recognized revenue and collected cash. It examines cancellations, sponsor funding, backlog rules, operating leverage, lease obligations, repurchases, leadership and the interpretation of book-to-bill alongside the dated quarterly accounts.

$INOResearch updated November 10, 2026PDF · 58 pages

INOVIO: Q3 results, VOCERYQ Launch Economics and the Closed November Financing

Accelerated approval of VOCERYQ on October 30, 2026, the RRP-001 evidence and the confirmatory requirement, third-quarter 2026 results of November 10 with a net loss of $49.2 million, cash of $48.4 million at September 30 before the offering that closed on November 9 with about $80.5 million of net proceeds, going-concern language beyond the fourth quarter of 2027, warrants, dilution, litigation and the wider pipeline.

$FATEResearch updated November 20, 2026PDF · 15 pages

Fate Therapeutics: FT819 and RECLAIM-LN

Research on FT819, RECLAIM-LN, clinical evidence, cash flow and capital structure.

$DRTSResearch updated November 16, 2026PDF · 19 pages

Alpha Tau: REGAIN evidence, ReSTART early 2027 and the FDA pathway

The November 16 REGAIN presentation and completed investor call, the early-2027 ReSTART topline target and possible FDA application, interim study limitations, IMPACT, cash, warrants and the current Health Score.

$CERTResearch updated November 5, 2026PDF · 17 pages

Certara Stock Research: Q3 Results, Software Growth and 2026 Outlook

Q3 2026 continuing results, software and services mix, adjusted EBITDA definition, cash and term loan, share count, repurchase capacity and updated 2026 outlook.

$CAPRResearch updated November 21, 2026PDF · 20 pages

Capricor Therapeutics After the Second Deramiocel CRL

FDA declined to approve deramiocel on November 20. Read the HOPE-3 findings, Capricor’s response, cash position and the choices after the second CRL.

$BDRXResearch updated November 21, 2026PDF · 19 pages

Biodexa Pharmaceuticals: Serenta and Cancer Data

Biodexa has two near-term tests. Its Serenta trial of eRapa in familial adenomatous polyposis was two-thirds enrolled in November and could reach a futility review in early 2027. Separately, the company needs financing to carry its programs toward those clinical milestones. June cash was £3.23 million before a July raise of US$3.5 million gross, and its licensed gastrointestinal stromal tumor program is preparing for a Phase 1 restart.

$AXSMResearch updated November 19, 2026PDF · 18 pages

Axsome Therapeutics: revenue up 52%, AXS-12 FDA decision due May 1, 2027

A full analysis of AUVELITY after its Alzheimer’s disease agitation approval, SUNOSI and SYMBRAVO, the AXS-12 review and the Phase 3 pipeline, third-quarter revenue of $259.7 million and a $12.9 million loss, $313.9 million of cash against $190.0 million of secured borrowings, options, insiders and holders.

$AUTLResearch updated November 19, 2026PDF · 20 pages

Autolus Therapeutics plc: AUCATZYL, lupus trials and financing

A full analysis of the AUCATZYL launch, evidence in leukemia and lupus, royalties, cash use and credit terms.

$ARCTResearch updated November 21, 2026PDF · 20 pages

ARCT Stock Hub: Arcturus Therapeutics News, Meiji and Rare Disease Trials

The report separates the Meiji equity investment and refund terms, the cystic fibrosis and OTC deficiency evidence, and the September financial results after the CSL settlement.

$ALTResearch updated November 13, 2026PDF · 40 pages

ALT Stock Hub: Altimmune News, Pemvidutide and MASH Trials

Altimmune is developing pemvidutide across MASH, alcohol use disorder and alcohol-associated liver disease. On November 9, 2026 , the company presented the RECLAIM Phase 2 alcohol use disorder data in a late-breaker session at AASLD and reported that the trial met its primary endpoint, with heavy drinking days falling by 4.20 per week on pemvidutide versus 2.75 on placebo (company-reported). Third-quarter results released on November 12 reported $480 million in cash, cash equivalents and investments at September 30, 2026 and a quarterly net loss of $31.6 million; the same day the 48-week IMPACT Phase 2b MASH data were published in The Lancet Gastroenterology & Hepatology . An FDA End-of-Phase 2 meeting on alcohol use disorder is scheduled for December 2026 ; RESTORE topline remains guided to H2 2027 and PERFORMA 52-week data to 2029 . Equity financings enlarged the share count to 194.5 million, and a $10 million Hercules draw on October 27 came after the September balance-sheet date.

$ZVRAResearch updated November 18, 2026PDF · 14 pages

Zevra: Q3 Earnings, Commercial Cash, European Review and Celiprolol

Twelve analytical chapters plus falsifiers: commercial access and concentration, European review, NPC trial evidence and limitations, celiprolol and DiSCOVER, Q3 and nine-month financial statements, EPS and non-cash gains, operating cash, investments, debt repayment, taxes and rebates, dilution, ownership, insider transactions and risk scenarios. Daily price and volume chart with SMA 50/200 on page 2 through November 3, plus eight complete FAQ answers.

$VTRSResearch updated November 17, 2026PDF · 15 pages

Viatris research report

Completed Pacira acquisition and integration risks, third-quarter results, cash and debt, the December meloxicam FDA target, commercial portfolio and financial resilience. Earlier analytical chapters retain their stated dates.

$SLNResearch updated November 12, 2026PDF · 13 pages

Silence Therapeutics: third-quarter cash of $247.7 million and a $12.4 million net loss, with the Merck KGaA closing expected in Q1 2027

Silence reported a third-quarter 2026 net loss of $12.4 million, or $0.08 per ADS, against $21.0 million a year earlier, with cash and cash equivalents of $247.7 million at September 30, including the August offering’s $201.3 million gross proceeds. Research and development expenses fell to $9.3 million from $20.5 million, and general and administrative expenses were $4.9 million. Silence had 186,609,073 ordinary shares outstanding at September 30, and continues to expect the Merck KGaA acquisition to close in the first quarter of 2027, subject to shareholder, court and regulatory approvals.

$SANAResearch updated November 19, 2026PDF · 15 pages

Sana Biotechnology: UP421 human evidence, SC451 timing and the September cash position

UP421 cell survival and function through 14 months in one recipient, set against SC451 as a separate stem-cell program, with the November 5 update targeting an SC451 trial start as early as 2026 and moving SG293 study initiation to the first quarter of 2027. Cash and marketable securities of $121.7 million at September 30, $108.9 million of nine-month operating cash use, $20.4 million of third-quarter GAAP net income driven by $63.4 million of noncash fair-value benefits and a continuing going-concern warning frame the financing question.

$EPRXResearch updated November 11, 2026PDF · 19 pages

Eupraxia Pharmaceuticals: third-quarter 2026 results, the US$125 million at-the-market program and the December RESOLVE interim

The November 10, 2026 third quarter reported a $15.2 million net loss, $34.6 million of nine-month operating cash use and $126.4 million in cash and short-term investments at September 30, with runway into the second half of 2028. The same day Eupraxia established a US$125 million at-the-market program with Jefferies, which it says it has no current plan to use near term; the report sets that against the 120-patient Phase 2b enrollment reached October 15 and the randomized interim expected in December 2026.

$CMPXResearch updated November 20, 2026PDF · 15 pages

Compass Therapeutics: Tovecimig and the Regulatory Path

Research on Tovecimig, regulatory evidence, clinical programs and financial position.

$BLLNResearch updated November 18, 2026PDF · 16 pages

BillionToOne: profitable growth, billing questions

A full analysis of third-quarter results and the guidance raise, average selling price and receivables, the November 18 short-seller report as allegations, internal controls, Illumina litigation, Oberland notes and insider sales.

$ZNTLResearch updated November 21, 2026PDF · 20 pages

ZNTL Stock Hub: Zentalis Pharmaceuticals News, DENALI and ASPENOVA

The integrated DENALI Part 2 readout, what the earlier survival and safety data show, the randomized ASPENOVA trial, and the August financing behind the September balance sheet. Includes scenarios, clinical sources, and FAQ.

$ZLABResearch updated November 21, 2026PDF · 19 pages

Zai Lab: Zoci and Regional Medicines

Zai Lab reported lower year-over-year third-quarter product sales and a small sequential recovery. The approved portfolio remains the main source of revenue as the company invests in zoci and other internally developed programs. The announced private placement is a separate financing event. The September financial position and the status of development milestones are assessed on their own dates.

$VRTXResearch updated November 21, 2026PDF · 19 pages

Vertex Pharmaceuticals: Kidney Trials and Crinetics

Vertex’s cystic fibrosis franchise is funding expansion into gene-edited therapy, acute pain, endocrine disease and kidney medicine. The Crinetics acquisition added a commercial endocrine business and term debt. Acquisition expenses weighed on third-quarter GAAP results, while adjusted net income edged lower.

$VCREResearch updated November 21, 2026PDF · 18 pages

Vicore Pharma: Buloxibutid and ASPIRE

Vicore Pharma’s investment case now rests on a single randomized question: whether oral buloxibutid, an angiotensin II type 2 receptor agonist, can slow forced vital capacity decline in idiopathic pulmonary fibrosis better than placebo when ASPIRE reports 52-week topline in mid-2027. The October 2026 futility review let the 378-patient trial continue unchanged, but it disclosed no efficacy signal and the company remains blinded. With SEK 772.0 million of cash and short-term investments at September 30, 2026 and runway guided into the second half of 2028, the balance sheet covers the readout; it does not fund a Phase 3 program.

$TNGXResearch updated November 12, 2026PDF · 17 pages

Tango Therapeutics: third-quarter 2026 results, $977.5 million of liquidity and the front-line pancreatic Phase 3 plan

The November 9, 2026 third quarter reported a net loss of $68.4 million, or $0.39 per share, and cash, cash equivalents and marketable securities of $977.5 million at September 30 against nine-month operating cash use of $120.4 million. Tango plans a randomized front-line Phase 3 of vopimetostat 200 mg plus daraxonrasib 100 mg versus chemotherapy in MTAP-deleted pancreatic cancer to start in the first half of 2027, with lung monotherapy and TNG456 data guided for January 2027; the report sets the 82% response rate in 22 evaluable patients against the denominators, safety and combination economics.

$IVAResearch updated November 19, 2026PDF · 19 pages

Inventiva: the NATiV3 Q4 window, the November 23 cash report and the financing built around the readout

The Phase 3 NATiV3 has finished treating, the last patient visit was completed on September 2 and topline remains guided to the fourth quarter of 2026 with no date. The report keeps 1,009 main-cohort and 410 exploratory-cohort patients, the €233.9 million of cash and deposits at June 30 against €45.4 million of half-year operating cash use, the runway stated to the end of the second quarter of 2027 and the conditional extension to the start of the first quarter of 2028. Third-quarter revenues and cash are due on November 23, 2026 before the European and United States open; the AASLD posters of November 5 and 7 have been presented and are separate from the topline.

$IRONResearch updated November 21, 2026PDF · 21 pages

IRON Stock Hub: Disc Medicine News, Bitopertin and APOLLO

Disc Medicine’s APOLLO results and FDA resubmission path, the competitive landscape in protoporphyria and polycythemia vera, selcodebart, September financials, October equity financing, and the November ATM. Includes scenarios, clinical sources, and FAQ.

$IONSResearch updated November 21, 2026PDF · 18 pages

Ionis Pharmaceuticals: Hibsago and RNA Medicines

Ionis enters late 2026 as a commercial-stage RNA-medicine company whose revenue still leans on partner royalties while its own launches absorb cash. Third-quarter revenue rose to $242.7 million, but management halved 2026 TRYNGOLZA sales guidance to roughly $50 million and reaffirmed total revenue, operating-loss and year-end cash targets. The investment question is no longer whether the science works; it is whether owned-product economics, milestone timing and a $1.9 billion liquidity base can carry the company to self-funding before convertible maturities and royalty obligations claim their share.

$FDMTResearch updated November 13, 2026PDF · 15 pages

FDMT Stock Hub: 4D Molecular Therapeutics News, Genetic Medicines and Clinical Data

4D Molecular Therapeutics is testing a sustained retinal therapy with a clear medical objective: protect vision with fewer repeated injections. 4D-150 remains experimental; all product candidates are unapproved. At the October 21, 2026 Investor Day, the company reported 523 randomized patients in 4FRONT-1 and 531 in 4FRONT-2. Wet AMD topline results remain expected in Q2 2027 and H2 2027. The DME Phase 3 study 4SIGHT began enrolling in September. Its planned 514 patients and separate clinical questions broaden the opportunity while adding cost and a longer timeline. The clinical case rests on controlled vision outcomes, supplemental-injection burden and safety. The stock case also depends on operating cash use, funding terms, manufacturing readiness and dilution.

$ELTXResearch updated November 21, 2026PDF · 17 pages

Elicio Therapeutics: ELI-002 and Clinical Funding

Elicio Therapeutics is a clinical-stage immunotherapy company. Its lead asset, camupepimut (ELI-002 7P), missed the primary outcome in a Phase 2 pancreatic cancer study. The next decisions concern the evidence needed for further development and the financing available to support it.

$CRBPResearch updated November 21, 2026PDF · 17 pages

Corbus Pharmaceuticals: CRB-701 and CRB-913

Corbus is developing two clinical-stage treatments. The registrational TEMPO-1 study evaluates sutantatug envedotin (CRB-701) in previously treated oropharyngeal cancer. In obesity, the Phase 1b CANYON-1 study reported a 5.0% placebo-adjusted weight reduction at 12 weeks in its highest-dose group. The programs require different evidence. TEMPO-1 assesses tumor response and survival, while CRB-913 needs longer follow-up on weight loss, treatment discontinuation and safety. Both programs draw on the same cash and carry separate license obligations.

$BLSMResearch updated November 13, 2026PDF · 16 pages

BLSM Stock Hub: BlossomHill Therapeutics News, Precision Oncology and Pipeline

BlossomHill Therapeutics is developing oral small molecules for cancers with important treatment gaps. BH-30643 leads the portfolio through SOLARA, with early activity in EGFR C797S resistance. On November 9, 2026 the company reported alignment with the FDA, after its end-of-Phase 1 meeting, on 50 mg twice daily as the recommended Phase 2 dose, and outlined SOLARA-2, a single-arm pivotal Phase 2 study of about 150 patients designed with registrational intent, with first dosing expected in Q1 2027. The reported response signal is clinically interesting, while confirmation, durability and liver safety remain decisive. BH-30236 adds a distinct CLK and RNA-splicing approach in leukemia; BH-501284 supplies earlier pan-KRAS opportunity. A wholly owned portfolio and recent IPO funding provide flexibility, while clinical translation, study execution, competition and dilution determine how much of that opportunity can become value for each BLSM share. On November 12, 2026 BlossomHill reported $224.9 million of cash and equivalents at September 30 and kept its funding forecast into Q2 2028. The November 12 regular-session close was $14.84 (-7.57% versus $16.055 on November 11).

$ABUSResearch updated November 20, 2026PDF · 19 pages

Arbutus Biopharma: AB-101 and capital return

Research on AB-101, imdusiran, the completed tender and the Moderna settlement.

$VRCAResearch updated November 13, 2026PDF · 13 pages

VRCA Stock Hub: Verrica Pharmaceuticals News, YCANTH and Clinical Development

Verrica combines an approved dermatology product, an indication-expansion readout and a constrained financing position. Rising applicator dispensing supports the commercial case, but is not identical to recognized sales or collected cash. COVE-2 could extend YCANTH’s opportunity if efficacy, safety and later regulatory work support common-warts use. The September analyses concern existing molluscum trials and cannot answer that question. Meanwhile, secured borrowing (fully available since October 22, 2026) and deferred partner-funded costs create claims on future resources. A balanced assessment follows demand, cash conversion, financing access and clinical results together; VP-315 is an additional development option, not a substitute for those immediate tests.

$SGMTResearch updated November 12, 2026PDF · 16 pages

Sagimet Biosciences: the third-quarter balance sheet, the AURORA execution and the mid-2029 funding horizon

Sagimet reported third-quarter 2026 cash, cash equivalents and marketable securities of $275.8 million at September 30, or $355.8 million pro forma for the October offering, with a quarterly net loss of $19.1 million and nine-month operating cash use of $31.822 million. The report follows the U.S. AURORA phase 3 acne study, the TVB-3567 phase 2 target by year-end 2026, the Chinese partner evidence and extension data, retained rights outside Greater China, the dilution map, risks, scenarios, sources and FAQ.

$SCYXResearch updated November 20, 2026PDF · 15 pages

SCYNEXIS: SCY-770 and SCY-247

Research on SCY-770, SCY-247, development funding and capital structure.

$RNXTResearch updated November 20, 2026PDF · 17 pages

RenovoRx: RenovoCath Sales and Survival Evidence

Research on RenovoCath, TIGeR-PaC, commercial demand and financing.

$NNVCResearch updated November 21, 2026PDF · 17 pages

NanoViricides: NV-387 and Antiviral Trials

A public equity profile of NanoViricides, Inc. (NYSE American: NNVC) covering the fiscal quarter ended September 30, 2026, the company’s cash position, related party arrangements, shelf offerings and governance, with a high-level regulatory chronology and the next announced milestone.

$MBRXResearch as of November 16, 2026PDF · 14 pages

Moleculin Biotech: MIRACLE Part A dosing complete, with Part B planned for the first half of 2027

Moleculin completed dosing in the 90-patient MIRACLE Part A population on October 30, 2026 and repeats that the comprehensive readout is guided to the first quarter of 2027, with the first interim analysis due as a poster at ASH on December 12-15. The November 16 release places Part B and a physician-sponsored pancreatic-cancer trial in the first half of 2027, third-line and pediatric AML studies in the first half of 2028, Part B recruitment and primary second-line data in the second half of 2028 and a rolling NDA in 2028-2029. The Q3 Form 10-Q reports $7.287 million of cash at September 30, nine-month operating cash use of $21.738 million, substantial doubt about going concern and a Nasdaq Hearings Panel exception granted November 12 with conditions to March 15, 2027. Health Score 2.20.

$IMVTResearch updated November 21, 2026PDF · 15 pages

Immunovant: Imeroprubart and Autoimmune Trials

Immunovant’s fiscal second quarter of 2027 closed with $722.3 million in cash and a narrowed net loss, while the imeroprubart rheumatoid arthritis maintenance data and the company’s decision to deprioritize Sjögren’s disease reset the near-term clinical narrative. The quarter highlights company-specific scenarios, the operating model, and the two lead development programs using the quarterly filing and the November 9, 2026 corporate release.

$DMACResearch updated November 13, 2026PDF · 14 pages

DMAC Stock Hub: DiaMedica Therapeutics News, DM199 and Clinical Development

DiaMedica Therapeutics is developing DM199, a recombinant human KLK1 protein, to improve vascular function in acute ischemic stroke, preeclampsia and fetal growth restriction. ReMEDy2 reached 200 enrolled patients on October 22. Its Q1 2027 interim concerns sample size or futility, and the company stays blinded; final enrollment may range from 300 to 728 if it proceeds. Preliminary FGR findings are scheduled for November 24. Early pregnancy observations support further study, while the key questions remain clinical outcomes, maternal-fetal safety and financing. September 30 liquidity was $34.9M, and management now expects it to fund planned clinical studies and corporate operations into Q4 2027.

$CYTKResearch updated November 19, 2026PDF · 17 pages

Cytokinetics: the MAPLE-HCM label update, MYQORZO sales and the royalty debt

MYQORZO net product revenue was $44.5 million in the September 2026 quarter and $74.6 million in nine months, and on November 16, 2026 the FDA approved the supplemental application that adds the MAPLE-HCM results against metoprolol to the prescribing information, with the indication unchanged. The report covers the quarter, the non-obstructive filing due in the fourth quarter, cash of $1.58 billion, the Royalty Pharma debt at a 28.4% imputed rate, dilution, the 13G changes and the risks.

$CGTXResearch updated November 20, 2026PDF · 17 pages

Cognition Therapeutics: Zervimesine and DLB

Research on Zervimesine, DLB study design, grant funding and capital structure.

$VRDNResearch updated November 19, 2026PDF · 22 pages

Viridian: the first Lumvoa quarter, the November 9 VRDN-008 Phase 1 data and the elegrobart filing path

Third-quarter Lumvoa net product revenue of $24.671 million, more than 100 patients on therapy and $955.206 million of cash and marketable securities at September 30 sit alongside a $101.209 million quarterly net loss and $92.773 million of calculated operating cash use. The November 9, 2026 VRDN-008 Phase 1 results – 74% peak IgG reduction, a 15-18 day half-life and a planned registrational myasthenia gravis trial in mid-2027 – extend the pipeline beyond thyroid eye disease and stay separate from the Q1 2027 elegrobart BLA target.

$UNCYResearch as of November 16, 2026PDF · 16 pages

Unicycive: the OLC review, $58.972 million at September 30 and runway beyond 2027

Follows OLC’s two complete response letters, the second-vendor resubmission and the accepted FDA review with a March 25, 2027 PDUFA date, separating manufacturing compliance from clinical tolerability and commercial adoption. The third-quarter report showed a net loss of $6.997 million, cash and marketable securities of $58.972 million at September 30, nine-month operating cash use of $21.094 million and guidance that resources fund operations beyond 2027 including the OLC launch; 29,184,509 shares and 19,167,878 potentially dilutive securities, two securities actions and milestone-linked warrant expirations show how regulatory progress interacts with funding needs and dilution.

$TRDAResearch updated November 18, 2026PDF · 15 pages

Entrada Therapeutics: clean safety, small dystrophin, a short runway

A full analysis of the ENTR-601-44 and ENTR-601-45 cohorts, the 15 mg/kg dose step, VX-670, third-quarter accounts, the going-concern disclosure, insider and venture-holder sales and dilution.

$TRAXResearch updated November 4, 2026PDF · 20 pages

First Tracks: Q3 Financials, ANB033 Healing and October Financing

All fifteen analytical chapters: CD122 biology, controlled gluten-challenge data, distinct mucosal-healing test, safety and statistical limits, earlier IL-15 trials, EoE and planned expansion, rosnilimab and ANB101, Q3 financials and historical comparisons, separation accounting, cash flow, placement and resale terms, awards, ownership, management and competing treatments. Daily price and volume chart with SMA 50 on page 2; fewer than 200 post-listing sessions are available for SMA 200. Includes eight complete current FAQ answers and earlier dated clinical questions.

$TGTXResearch as of November 18, 2026PDF · 19 pages

TG Therapeutics: BRIUMVI Sales, Third-Quarter Results and Blue Owl Debt

BRIUMVI, clinical evidence, commercial performance, third-quarter results and financing.

$SVRAResearch updated November 19, 2026PDF · 23 pages

Savara: MOLBREEVI, the FDA Review and the Third-Quarter 2026 Results

The archived October 21, 2026 report on MOLBREEVI’s regulatory sequence, IMPALA-2 endpoints and conditional debt, with a dated third-quarter section: cash and investments of $129.6 million at September 30, a $43.0 million net loss and $42.5 million of operating cash use in the quarter, 220,623,511 shares on the November 9 cover, the Hercules and RTW terms, the November 22 FDA action date and a reassessed Merlintrader Health Score of 3.25 out of 5.

$STIMResearch updated November 21, 2026PDF · 20 pages

STIM Stock Hub: Neuronetics News, NeuroStar and the Perceptive Loan

Neuronetics’ third-quarter results and cash flow, the November equity issuance and Perceptive loan conditions, Greenbrook clinic economics, and the evidence and regulatory outlook for NeuroStar. Includes scenarios, ownership, sources, and FAQ.

$MSLEResearch updated November 20, 2026PDF · 15 pages

Satellos Bioscience: BASECAMP and FSHD

Research on Forazapadin, neuromuscular trials and financing.

$GRALResearch updated November 5, 2026PDF · 20 pages

GRAL Stock Research: GRAIL Q3 Results and Galleri FDA Review

Q3 financial results, Galleri clinical evidence, the FDA advisory votes, liquidity and dilution.

$FULCResearch updated November 13, 2026PDF · 11 pages

FULC Stock Hub: Fulcrum Therapeutics News, Operations and Capital

A proposed cash distribution and a small stake in a new migraine company: closing terms come first, clinical proof comes later. On November 12, 2026 Fulcrum disclosed a $7.0 million cash sale of its early-stage HbF assets, conditional on the merger, with proceeds expected to add to the pre-closing dividend. The November 12, 2026 regular-session close was $3.68 . Historical financial and clinical observations retain the dates shown below.

$BCDAResearch updated November 20, 2026PDF · 21 pages

BCDA Stock Hub: BioCardia News, CardiAMP and Helix

BioCardia’s November research examines the CardiAMP heart failure studies, the Japan filing window and the U.S. Helix device pathway. It reconciles September-quarter losses, operating cash use, the funding gap, warrants and Nasdaq listing risk against the company’s filings.

$BBOTResearch updated November 21, 2026PDF · 21 pages

BridgeBio Oncology: RAS Trials and Funding

BridgeBio Oncology Therapeutics is a pre-revenue, Phase 1-stage RAS and PI3Kα company whose investment case rests on two separable questions: whether three internally discovered inhibitors produce durable activity as combinations, and whether a balance sheet of $315.3 million at September 30, 2026 can carry that work into 2029 as management states. The company’s own disclosures supply early response rates and a funding horizon, but no randomized evidence, no revenue and no committed outside capital.

$ANABResearch updated November 13, 2026PDF · 18 pages

ANAB Stock Hub: AnaptysBio News, Jemperli and Quimilza Royalties

AnaptysBio is a focused royalty company following the First Tracks separation. Jemperli economics depend on partner sales, contractual thresholds and litigation; Quimilza has a December 12 FDA target . ANAB retains a 10% net-sales royalty , while the former Vanda milestone rights belong to First Tracks.

$VTGNResearch updated November 12, 2026PDF · 15 pages

Vistagen: the FDA Type C feedback on the LSAS endpoint, the 31% workforce reduction and the February 1 deadline

The November 9, 2026 regulatory update reports FDA feedback from a Type C meeting on using the Liebowitz Social Anxiety Scale as the primary endpoint in a future Phase 3 study, with recommendations on interim assessments; Vistagen plans a revised protocol, with no timing for the submission, a trial start or financing. The October 26 workforce reduction of approximately 31% carries about $1.0 million of estimated severance and termination costs and about $3.2 million of expected annual salary and benefits savings, against $31.730 million of June 30 cash and securities, $14.707 million of quarterly operating cash use and the February 1, 2027 Nasdaq bid-price deadline.

$SPROResearch updated November 21, 2026PDF · 20 pages

Spero Therapeutics: Operations and Capital

Spero Therapeutics has changed identity in 2026: its partnered oral antibiotic, Utebzi, reached FDA approval under GSK, while the company itself now rests on SP001, an in-licensed CD40L antibody that has yet to enter a U.S. trial. A $105 million royalty financing funded the pivot, converting future GSK payments into present cash and leaving a thin equity cushion. The hub separates partner evidence, company disclosure, accounting effects and obligations.

$PACBResearch updated November 19, 2026PDF · 17 pages

PacBio: the long-read business, the cash burn and the 2029-2030 debt wall

Third-quarter 2026 revenue was $40.6 million, up 6%, with a 33% gross margin and an operating cash use of $37.6 million; guidance was cut twice to $155-160 million and on November 10 the company signed an at-the-market agreement for up to $100 million. The report covers the two debt exchanges, the $641.0 million of convertible notes due in 2029 and 2030 against $199.4 million of cash, the platforms, the 13G changes and the risks.

$OSCRResearch updated November 21, 2026PDF · 19 pages

Oscar Health: ACA Insurance and Medical Costs

Oscar Health’s third quarter of 2026 shows an insurer whose economics have been transformed by disciplined pricing and a favorable risk-adjustment reset: revenue rose 72% year over year, the medical loss ratio fell to 84.0%, and the company raised full-year operating earnings guidance for a third time. The central question for the next twelve months is whether that improvement is structural or cyclical, because the fourth quarter will burn a large share of full-year profit, and 2027 pricing depends on policy variables — enhanced premium tax credits, cost-sharing reduction funding, and the 2027 payment notice — that sit outside management’s control.

$ONCYResearch updated November 12, 2026PDF · 16 pages

Oncolytics: the ASH myeloma poster, the SITC anal-cancer data and the Coherus supply agreement

The November 9, 2026 single-cell translational data in relapsed/refractory multiple myeloma will be presented as abstract 2183 at the ASH Annual Meeting on December 12, and the November 4 SITC data describe HPV-16-specific T cell expansion in anal cancer. Both are biomarker observations, not randomized efficacy results. On November 11 Oncolytics signed a clinical supply agreement with Coherus Oncology for LOQTORZI (toripalimab-tpzi) in squamous cell anal carcinoma, with the study anticipated to begin in the first quarter of 2027. The report keeps the conditional year-end REO 033 interim update, June cash of $4.115 million, the going-concern warning, the ATM and the January 19, 2027 Nasdaq deadline separate from any of those plans.

$MDGLResearch updated November 21, 2026PDF · 17 pages

Madrigal Pharmaceuticals: Rezdiffra and MASH

Madrigal reported its first profitable quarter in September 2026 as U.S. demand for Rezdiffra lifted net product revenue. The company still posted a loss for the first nine months. The next financial question is whether recurring product sales can support commercial expenses, debt service and multiple clinical programs through periods of variable cash flow. Rezdiffra’s present U.S. indication covers noncirrhotic MASH with moderate to advanced fibrosis. The cirrhosis studies address separate populations and retain their own clinical and regulatory risks.

$MANEResearch updated November 13, 2026PDF · 17 pages

Veradermics: twelve-month Study 302 data, the third-quarter cash position and the female readout

The 12-month Study 302 Part B results of November 9, 2026 — non-vellus hair counts up 43.9 hairs/cm² twice daily and 29.7 once daily at Month 12, with no new safety signals — and the third-quarter position of $798.4 million in cash, equivalents and marketable securities are set against the female Study 306 readout expected in the first half of 2027, with a $21.0 million quarterly net loss, 42,195,472 shares on November 5, endpoints and safety, competition and capital requirements.

$LPCNResearch updated November 21, 2026PDF · 18 pages

LPCN Stock Hub: Lipocine News, BLOOM and the Funding Runway

BLOOM is under way after an earlier Phase 3 miss. The report separates clinical evidence from the trial timeline, explains TLANDO licensing and September results, and follows the cash and equity issuance financing the next stage.

$IBIOResearch updated November 19, 2026PDF · 17 pages

iBio: the muscle-sparing antibodies, the human genetics and the cash

Fiscal 2026 closed with $76.7 million of cash and investments, a net loss of $33.0 million and a going-concern note that the company says is alleviated by the November financing. The report covers IBIO-600 and IBIO-610, their preclinical data and trial designs, the Activin E human genetics, the competitive field, the $500 million of authorized shares, the Frazier 13G/A change of basis and the risks.

$GPCRResearch updated November 18, 2026PDF · 14 pages

Structure Therapeutics: three Q4 readouts, the November 17 fireside chat and $1.24 billion of cash

Structure Therapeutics will take part in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026 at 12:00 p.m. GMT, an investor event announced on November 4 and separate from the three aleniglipron readouts still guided to the fourth quarter. The report keeps the third-quarter net loss of $144.8 million, $1,240.0 million of cash and short-term investments at September 30, runway guidance through the end of 2028, the November 15 ACCESS posters and the ACCOMPLISH topline expected in the second half of 2028.

$DCOYResearch updated November 21, 2026PDF · 19 pages

DCOY Stock Hub: Decoy Therapeutics News, Cash Runway and Clinical Entry

Examines the lead antiviral filing target, the gap between clinical plans and management’s runway, the September financial statements, cash restrictions, warrant exposure, Nasdaq and ownership.

$SYREResearch updated November 4, 2026PDF · 28 pages

Spyre Therapeutics: Q3 Financials, SKYWAY, SKYLINE and HS

All twenty-five analytical chapters and the falsification framework: antibody platform and licensing, three SKYLINE Part A cohorts, randomized Part B design, detailed SKYWAY results, SPY772 and SKYLIGHT, Q3 and nine-month financials, cash flows, preferred stock, completed warrant exercises, ATM and offering terms, ownership, management, market structure and risks. All five dated scientific and financial figures, daily price and volume chart with SMA 50/200 on page 2 through November 3, and eight complete FAQ answers.

$RAREResearch updated November 18, 2026PDF · 14 pages

Ultragenyx: two gene therapy approvals, $413 million of vouchers and a 20% workforce cut

GENGLYCOS was approved on an accelerated basis in August 2026 for glycogen storage disease type Ia and FAYUVI in full in September 2026 for Sanfilippo syndrome type A, and the two priority review vouchers they generated were sold or agreed for a combined $413 million. The company reported $173 million of third-quarter revenue, a $118 million net loss and $401 million of cash and marketable securities against $737 million at the end of 2025, cut about 20% of its workforce and guided 2027 research spending below $350 million with GAAP profitability reaffirmed for that year. The report covers the launch economics, the $1,186 million of liabilities for sales of future royalties, the negative equity, the pipeline that remains after the termination of UX701 and the closing of GTX-102, dilution and short interest.

$CRMDResearch as of November 18, 2026PDF · 19 pages

CorMedix: DefenCath TPN enrollment behind schedule, a possible alternative FDA path and Medicare Advantage by year-end

DefenCath, commercial execution, third-quarter results and capital structure.

$CGEMResearch updated November 13, 2026PDF · 20 pages

CGEM Stock Hub: Cullinan Therapeutics News, T-Cell Engagers and Zipalertinib

November 12, 2026: Cullinan said its partner Taiho Oncology completed the NDA submission for zipalertinib plus platinum-based chemotherapy in previously untreated EGFR exon-20-insertion lung cancer, made under FDA’s Real-Time Oncology Review program; if the FDA accepts the application, a PDUFA target action date will be assigned. Cash, investments and interest receivable were $313.8 million at September 30, with runway guided into 2029. The previously treated application keeps its February 27, 2027 target action date, while velinotamig lupus data were reported on November 8 and CLN-978 and CLN-049 data are scheduled for December. The central question remains whether deeper, durable responses can be achieved at doses that stay practical and safe.

$BLTEResearch updated November 12, 2026PDF · 15 pages

Belite Bio: the third quarter, $774.0 million in cash and no advisory committee for tinlarebant

Unaudited third-quarter 2026 results filed on Form 6-K on November 12: a net loss of $30.3 million, or $0.75 per share, research and development expense of $15.5 million and selling, general and administrative expense of $21.4 million, against $271.3 million of cash and $502.7 million of U.S. treasury bills and notes at September 30. The report sets the February 12, 2027 PDUFA target date, the company statement that the FDA will not convene an advisory committee, the DRAGON and PHOENIX evidence, the international filings and the launch spending against that single decision.

$LRMRResearch updated November 21, 2026PDF · 20 pages

Larimar Therapeutics: Nomlabofusp and the BLA

Larimar Therapeutics is a clinical-stage company whose lead asset, nomlabofusp, targets Friedreich ataxia. On November 9, 2026 the company announced completion of a rolling Biologics License Application for nomlabofusp, and on 16 November it reaffirmed that status alongside third-quarter accounts. The filing seeks accelerated approval covering adults and pediatric patients. Acceptance is not yet attested, no target action date appears in either release, and the confirmatory placebo-controlled program remains in enrollment. This research note examines the evidence base, the filing posture, the financial position and the company-specific tests that follow from those facts.

$ABVXResearch updated November 21, 2026PDF · 18 pages

ABVX Stock Hub: Abivax News, Obefazimod and the FDA Filing Path

Abivax’s pivotal ulcerative colitis results, the November response to a short report, the year-end FDA submission target and December reporting date, the June IFRS accounts and July equity financing, and the Crohn’s Phase 2b program. Includes scenarios, sources, and FAQ.

$RCKTResearch updated November 19, 2026PDF · 19 pages

Rocket Pharmaceuticals: FDA-aligned Danon trial, $279.4 million of cash and runway into Q3 2028

A full analysis of the 12-patient pivotal RP-A501 trial and the 2025 clinical hold, KRESLADI approval and launch, the $180 million voucher sale, the Hercules loan and its covenants, third-quarter accounts, $124.1 million of nine-month operating cash use, dilution, litigation, insiders and holders.

$EDSAResearch updated November 21, 2026PDF · 20 pages

Edesa Biotech: EB06 and Vitiligo Development

Edesa develops immunology treatments. Its fiscal third-quarter accounts show rising research costs and material uncertainty about its ability to continue as a going concern. The August equity offering changed its capital structure, and the November Japanese license for paridiprubart added a fixed upfront obligation for Kyorin alongside contingent milestones. EB06, the investigational vitiligo antibody, remains an independent clinical question. Edesa expects topline data from the placebo-controlled study in the fourth quarter of 2027.

$AMLXResearch updated November 15, 2026PDF · 29 pages

Amylyx: Q3 Results, Avexitide Filing and the LUCIDITY Program

Detailed Phase 3 LUCIDITY results released on November 14 and presented at ObesityWeek on November 15, Q3 results, financing and runway, the avexitide NDA targeted by year-end 2026, a price chart to the November 13 close and the Health Score of 4.25.

$XBIOResearch updated November 13, 2026PDF · 13 pages

Xenetic Biosciences: DNase, CAR T and the Santersus combination

A first patient dosed in lymphoma puts the DNase hypothesis into clinical testing, while the proposed Santersus combination would transform the pipeline, control and shareholder denominator. The edition adds the November 13, 2026 results release: four first-in-class programmes with sepsis and lupus in pivotal stage under FDA Breakthrough Device Designation, the Phase I study NCT07361224 in large B-cell lymphoma, the expected first-quarter 2027 closing and the planned Santersus Bio, Inc. name with ticker SNTS.

$ADMAResearch updated November 18, 2026PDF · 14 pages

ADMA Biologics: ASCENIV sales and cash generation

A full analysis of ADMA’s product mix, distributor concentration, cash generation, debt-financed repurchases and equity awards.

$MISTResearch updated November 18, 2026PDF · 14 pages

Milestone: a CARDAMYST launch at $1 million a quarter and a runway built to reach 2028

CARDAMYST, approved on December 12, 2025, produced $1.0 million of product revenue in the September quarter, up 73% sequentially, from about 3,400 prescriptions written by about 1,600 prescribers, with payer coverage at roughly two-thirds of commercially covered lives. The company held $145.4 million of cash and investments, announced a program to cut operating expenses by about 30% to extend the runway into late 2028, and faces the topline of its phase 3 trial in atrial fibrillation with rapid ventricular rate in the second half of 2028. The report covers the launch economics, the RTW convertible notes at $60.2 million and the royalty obligation at $82.8 million, the 2029 payment-in-kind extension, the leadership changes, dilution to 124.5 million shares plus 16.4 million pre-funded warrants, short interest at 24.83 days of volume and the October Nasdaq notice on the bid price.

$BMEAResearch as of November 18, 2026PDF · 18 pages

Biomea Fusion: third-quarter cash, the going-concern repeat and the ObesityWeek poster

Clinical development, pipeline milestones, third-quarter results and financing.

$TYRAResearch updated November 11, 2026PDF · 17 pages

Tyra Biosciences: third-quarter 2026 results, the 2027 sentinel timing and the post-financing share base

The November 10, 2026 third quarter reported $700.5 million of cash and marketable securities at September 30 with runway guidance through 2030, a $51.1 million net loss on $43.1 million of research spending, and the BEACH301 safety-sentinel readout now guided to 2027 rather than the end of the first quarter. The report sets the SURF302 response data, the September financing terms, the 84.5 million economic share base including pre-funded warrants, the February 2027 competitor action date, scenarios, sources and FAQ.

$TENXResearch updated November 18, 2026PDF · 14 pages

Tenax: what LEVEL-2 can test and how the program is funded

A full analysis of LEVEL and LEVEL-2, the FDA Type C meeting, the Orion agreement, September-quarter results, cash need, warrants and ownership.

$QTTBResearch updated November 21, 2026PDF · 18 pages

Q32 Bio: Bempikibart and the Pivotal Program

Q32 Bio is preparing for a registration-directed program with a recapitalized balance sheet and one lead clinical asset, bempikibart, in alopecia areata. The September 30, 2026 quarter shows how $289.6 million of cash was assembled through four equity financings in nine months, while the evidence base is an open-label Phase 2a Part B, a placebo-comparison Part A and the earlier SIGNAL-AD experience. The open questions are regulatory design, comparability against approved Janus kinase inhibitors, and whether durability after drug withdrawal survives a controlled trial.

$QNTMResearch updated November 13, 2026PDF · 16 pages

Quantum BioPharma: the 10-for-1 consolidation approved, the Class A placement and the Lucid-MS test

Shareholders approved on November 10, 2026 a consolidation of up to ten pre-consolidation shares for one, with 97.022% of votes cast in favour and no ratio or effective date announced, and disinterested Class B holders authorised further Class A multiple voting shares to keep that class at up to 70% of the vote. On November 9 the company closed a placement of 26 Class A shares at C$3.11 each for C$80.86 gross, subscribed in equal parts by entities linked to Chief Executive Officer Zeeshan Saeed and director Anthony Durkacz, taking the Class A block to 68 shares and about 68.22% of the votes. The report now carries the September 30, 2026 interim figures — cash of US$3.556 million, digital assets of US$8.659 million and working capital of US$5.468 million that management considers sufficient for twelve months — and keeps the Lucid-MS Phase 2 clearance and the Unbuzzd listing plan separate from any completed transaction.

$PMVPResearch updated November 20, 2026PDF · 22 pages

PMV Pharmaceuticals: Rezatapopt, PYNNACLE and the financing behind the ovarian filing

The November 20 edition analyzes the PYNNACLE ovarian and all-cohort results presented at ENA, the planned filing, Q3 cash use, the September offering and the FDA-linked warrant reset.

$PLXResearch updated November 18, 2026PDF · 16 pages

Protalix: partner orders and cash conversion

A full analysis of Elfabrio and Elelyso supply contracts, working capital, cash conversion, PRX-115 and share issuance.

$PCVXResearch updated November 5, 2026PDF · 19 pages

Vaxcyte: VAX-31, OPUS evidence, Q3 2026 results and financing

Dated research on Vaxcyte after its third-quarter 2026 results of November 4, 2026: the VAX-31 OPUS-1 pivotal adult results and serotype-level comparisons, the fully enrolled OPUS-2 and OPUS-3 trials and the infant calendar, VAX-A1, cash, cash equivalents and investments of $2,264.4 million at September 30 before approximately $1.1 billion of October net proceeds, the equity and convertible-note financing, dilution and the Health Score. Daily price chart through the November 4, 2026 close.

$APMDResearch updated November 21, 2026PDF · 18 pages

APMD Stock Hub: Apnimed News, AD109 and the FDA Review

Apnimed’s AD109 FDA review, SynAIRgy and LunAIRo evidence, treatment persistence, launch economics, September-quarter cash, credit terms and equity dilution.

$AGENResearch updated November 5, 2026PDF · 20 pages

Agenus: Q3 Results, BOT+BAL Access and ROBBIN

Q3 results, noncash royalties, BOT+BAL access and the Phase 3 ROBBIN development plan.

$XRTXResearch updated November 21, 2026PDF · 19 pages

XORTX Therapeutics: XORLO and Funding

XORTX Therapeutics Inc. (Nasdaq: XRTX) reported unaudited IFRS interim financial statements for the three and nine months ended September 30, 2026, showing a cash balance of $318,846 and a nine-month net loss of $2,881,306. This research note examines company-specific scenarios, the business model, the XRx-026 gout program, and the XRx-101 and VB4-P5 assets, distinguishing financing and regulatory events from operating science.

$COGTResearch updated November 6, 2026PDF · 15 pages

Cogent: bezuclastinib, third-quarter results and regulatory steps

The report follows bezuclastinib across clinical populations and regulatory milestones, with attention to study design and safety. It adds the third-quarter 2026 results — $791.1 million of cash and securities at September 30, a $111.4 million net loss and funding into late 2028 — and assesses spending, capital structure and commercialization requirements while distinguishing strong trial results from completed approval or future sales.

$ALMSResearch updated November 21, 2026PDF · 18 pages

Alumis: Envudeucitinib and the Psoriasis Filing

Alumis enters the winter of 2026 with a late-stage psoriasis asset, a planned fourth-quarter NDA, a failed lupus trial with a biomarker-defined subgroup signal, and a going-concern warning set against $431.3 million of liquidity. The thesis turns on separating three things the company’s language tends to blend: company-reported trial evidence, regulatory milestones still ahead, and a funding gap that the cash runway statement and the going-concern assessment describe differently.

$BFRIResearch updated November 19, 2026PDF · 18 pages

Biofrontera Inc.: Ameluz launch, lamp supply and funding

A full analysis of Ameluz, the FDA approvals and pending application, the lamp transition, September liquidity and capital.

$CINGResearch updated November 18, 2026PDF · 14 pages

Cingulate: the CTx-1301 complete response letter, a resubmission window and the cost of waiting

The application for CTx-1301 drew a complete response letter on June 1, 2026 that asked only for chemistry, manufacturing and controls information; the company guides to a resubmission between December 2026 and January 2027, with a two-month Class 1 or six-month Class 2 review to follow. The report covers the September quarter with a $7.7 million net loss and $23.2 million of cash, the $14.2 million of selling, general and administrative expense already committed to commercial readiness through Indegene, the $12.0 million private placement and the $22.5 million drawn under the at-the-market and Lincoln Park facilities, the share count that doubled to 14.96 million, the going-concern note, the register and short interest.

$CANFResearch updated November 18, 2026PDF · 15 pages

Can-Fite BioPharma: two pivotal interims against the warrant chain

A full analysis of the psoriasis interim cohort, blinded liver-cancer survival, pancreatic and Lowe syndrome data, half-year accounts, runway and the 2026 warrant inducements.

$SCTXResearch updated November 19, 2026PDF · 18 pages

SCTX Stock Hub: Scribe Therapeutics News, Gene Regulation and Trials

Scribe is dosing STX-1150, a PCSK9 epigenetic silencing therapy, in a first-in-human Phase 1 that the trial registry now lists as recruiting at three sites in Australia and New Zealand. The company closed a $155.5 million IPO and private placement in July, reported $174.2 million of cash, cash equivalents and marketable securities at September 30, 2026, holds $25.7 million of CIRM awards for two more cardiometabolic programs and guides cash into the first half of 2029. The technology is early: no human efficacy data exist before the first half of 2027.

$CLDXResearch updated November 6, 2026PDF · 17 pages

Celldex: Third-Quarter Cash, the 2027 BLA Path and Barzolvolimab Safety

Third-quarter 2026 results: $650.3 million of cash and securities at September 30, $65.0 million of quarterly operating cash use, a $75.6 million net loss and funding guidance through 2028. EMBARQ-CSU evidence, anaphylaxis risk, the planned 2027 BLA, the new November shelf and the dilution channels.

$ATTOResearch updated November 9, 2026PDF · 14 pages

Attovia: Week 12 Phase 1b data, Q3 cash and the ATTUNE Phase 2 plan

Third-quarter 2026 net loss of $22.3 million and $395.9 million of cash, cash equivalents and marketable securities at September 30, with runway guided into 2030. The report covers the complete Week 12 ATTO-1310 Phase 1b results in chronic pruritus and high-itch atopic dermatitis, ATTO-2306 and ATTO-1091, option dilution and the ATTUNE Phase 2 trials planned for the first half of 2027.

$ACIUResearch updated November 4, 2026PDF · 27 pages

AC Immune: Q3 Resources, VacSYn Evidence and the Updated Clinical Windows

All sixteen analytical chapters, seven historical questions and five original historical financial figures, covering VacSYn design and week-100 evidence, antibody responses versus clinical efficacy, ACI-19764, owned and partnered programs, Q3/9M IFRS results, resources and deferred revenue, complete dated H1 cash flows, share/treasury/ATM context, governance and scenarios. Daily price/volume chart with SMA 50/200 on page 2, reassessed five-pillar Health Score and eight complete current FAQ answers.

$ALDXResearch updated November 9, 2026PDF · 19 pages

Aldeyra Therapeutics: the reproxalap appeal, cash runway and the next NDA steps

Aldeyra’s formal appeal of the reproxalap CRL, submitted on October 26, is distinct from a subsequent NDA resubmission or approval. The report examines the evidence dispute, the November 9 request to transfer the ADX-2191 PVRL IND review and the withdrawn Special Protocol Assessment, AbbVie optionality, September 30 cash, operational runway and future dilution. Financial period: September 30; Health Score assessed November 9.

$SLSSnapshot as of September 3, 2026PDF · 12 pages

SELLAS Life Sciences: expanded sentiment snapshot ahead of the REGAL 80th event

Expanded cross-platform sentiment snapshot from September 3, 2026: social-platform score and the bullish/bearish tagged split, dedicated-forum conviction, long-form investor debate, news flow and short positioning, read against the price move from the late-August peak. Reference price $13.79, REGAL status at 78 of 80 events. A dated observation, not a recommendation.

A biotech research index, not just a calendar

This page is the central Merlintrader index for company-level biotech research. It connects readers to analysis of pipelines, lead assets, FDA catalysts, clinical evidence, cash runway, dilution risk, management execution and market context. Unlike a simple catalyst calendar, this page helps you move from a date or headline to the deeper company questions that matter: what the asset does, what the next catalyst is, how strong the balance sheet looks and what risks could change the setup.

XBI sector reference chart

XBI biotech sector proxy chart from Finviz

Daily chart of the SPDR S&P Biotech ETF (XBI), a common reference for the sector. Affiliate link.

Browse biotech stock hubs

Every company in our biotech coverage has a stock hub with the current situation: latest news, key data, the next catalyst and the risks. Search by ticker or company name.

Open the biotech stock hub directory (258 companies)
$ABCL AbCellera Biologics$ABEO Abeona Therapeutics$ABUS Arbutus Biopharma Corporation$ABVX Abivax SA$ACAD Acadia Pharmaceuticals, Inc.$ACIU AC Immune$ACRS Aclaris Therapeutics$ADCT ADC Therapeutics$ADMA ADMA Biologics$AGEN Agenus Inc.$AGIO Agios Pharmaceuticals$AKBA Akebia Therapeutics$ALDX Aldeyra Therapeutics$ALLO Allogene Therapeutics$ALMS Alumis$ALNY Alnylam Pharmaceuticals$ALT Altimmune$AMLX Amylyx Pharmaceuticals$AMRN Amarin Corporation$AMRX Amneal Pharmaceuticals$ANAB AnaptysBio$ANL Adlai Nortye$ANNX Annexon$APMD Apnimed$AQST Aquestive Therapeutics$ARCT Arcturus Therapeutics$ARDX Ardelyx$ARQT Arcutis Biotherapeutics$ARTL Artelo Biosciences$ARTV Artiva Biotherapeutics$ARWR Arrowhead Pharmaceuticals$ATTO Attovia Therapeutics$ATYR aTyr Pharma$AUPH Aurinia Pharmaceuticals$AUTL Autolus Therapeutics$AVTX Avalo Therapeutics$AVXL Anavex Life Sciences$AXSM Axsome Therapeutics$BBIO BridgeBio Pharma$BBOT BridgeBio Oncology Therapeutics$BCDA BioCardia$BCRX BioCryst Pharmaceuticals$BCTX BriaCell Therapeutics$BDRX Biodexa Pharmaceuticals$BEAM Beam Therapeutics$BFRI Biofrontera Inc.$BHVN Biohaven$BLLN BillionToOne$BLSM BlossomHill Therapeutics$BLTE Belite Bio$BMEA Biomea Fusion$BTSG BrightSpring Health Services$CADL Candel Therapeutics$CANF Can-Fite BioPharma$CAPR Capricor Therapeutics$CATX Perspective Therapeutics, Inc.$CBIO Crescent Biopharma$CELC Celcuity$CERT Certara$CGEM Cullinan Therapeutics$CGTX Cognition Therapeutics$CING Cingulate Inc.$CLDX Celldex Therapeutics$CLGN CollPlant Biotechnologies$CLYM Climb Bio$CMPS Compass Pathways$CMPX Compass Therapeutics$CODX Co-Diagnostics$COGT Cogent Biosciences$CORT Corcept Therapeutics$CRBP Corbus Pharmaceuticals$CRDF Cardiff Oncology$CRDL Cardiol Therapeutics$CRMD CorMedix$CRSP CRISPR Therapeutics$CTNM Contineum Therapeutics, Inc.$CYTK Cytokinetics$DCOY Decoy Therapeutics$DFTX Definium Therapeutics$DMAC DiaMedica Therapeutics$DNLI Denali Therapeutics Inc.$DNTH Dianthus Therapeutics$DRMA Dermata Therapeutics$DRTS Alpha Tau Medical$DTIL Precision BioSciences$DYN Dyne Therapeutics$EDSA Edesa Biotech$ELTX Elicio Therapeutics$EPRX Eupraxia Pharmaceuticals$ETON Eton Pharmaceuticals$EWTX Edgewise Therapeutics$EYPT EyePoint Pharmaceuticals$FATE Fate Therapeutics$FBIO Fortress Biotech$FDMT 4D Molecular Therapeutics$FULC Fulcrum Therapeutics$GERN Geron Corporation$GMAB Genmab A/S$GPCR Structure Therapeutics$GRAL GRAIL, Inc.$GUTS Fractyl Health$HELP Helus Pharma$HIMS Hims & Hers Health$HRMY Harmony Biosciences Holdings, Inc.$HUMA Humacyte$IBIO iBio, Inc.$IBRX ImmunityBio$ICU SeaStar Medical$IDYA IDEAYA Biosciences$IMCR Immunocore Holdings plc$IMRX Immuneering Corporation$IMUX Immunic$IMVT Immunovant$INBX Inhibrx Biosciences, Inc.$INCY Incyte$INDV Indivior$INO INOVIO Pharmaceuticals$INTS Intensity Therapeutics$IONS Ionis Pharmaceuticals$IOVA Iovance Biotherapeutics$IRD Opus Genetics$IRON Disc Medicine$IVA Inventiva$KNSA Kiniksa Pharmaceuticals$KOD Kodiak Sciences$KPTI Karyopharm Therapeutics$KRRO Korro Bio$KRYS Krystal Biotech, Inc.$KYMR Kymera Therapeutics$KYTX Kyverna Therapeutics, Inc.$LBRX LB Pharmaceuticals$LEGN Legend Biotech$LFWD Lifeward$LGND Ligand Pharmaceuticals Incorporated$LGVN Longeveron$LPCN Lipocine$LRMR Larimar Therapeutics$LXRX Lexicon Pharmaceuticals$MANE Veradermics$MBOT Microbot Medical$MBRX Moleculin Biotech$MDAI Spectral AI$MDGL Madrigal Pharmaceuticals$MEDP Medpace$MEDS DataMeds AI$MIRM Mirum Pharmaceuticals, Inc.$MIST Milestone Pharmaceuticals Inc.$MLYS Mineralys Therapeutics$MNDR Mobile-health Network Solutions$MNKD MannKind Corporation$MNPR Monopar Therapeutics Inc.$MRNA Moderna$MSLE Satellos Bioscience$MTVA MetaVia$MYGN Myriad Genetics, Inc.$NAUT Nautilus Biotechnology$NKTR Nektar Therapeutics$NNVC NanoViricides, Inc.$NRXP NRx Pharmaceuticals$NTLA Intellia Therapeutics$NUVB Nuvation Bio Inc.$NVAX Novavax$NVCR Novocure$NVO Novo Nordisk$NYXH Nyxoah$OCGN Ocugen$OCS Oculis Holding AG$OCUL Ocular Therapeutix$OGN Organon$OMER Omeros Corporation$ONCY Oncolytics Biotech$ORIC ORIC Pharmaceuticals$ORKA Oruka Therapeutics$OSCR Oscar Health$OTLK Outlook Therapeutics$PACB Pacific Biosciences of California, Inc.$PCVX Vaxcyte$PDSB PDS Biotechnology$PEPG PepGen Inc.$PGEN Precigen$PHVS Pharvaris$PLX Protalix BioTherapeutics$PMVP PMV Pharmaceuticals$PRAX Praxis Precision Medicines$PRME Prime Medicine$PROK ProKidney$PTGX Protagonist Therapeutics, Inc.$PYPD PolyPid Ltd.$QNTM Quantum BioPharma$QTTB Q32 Bio$QURE uniQure$RAPP Rapport Therapeutics$RARE Ultragenyx Pharmaceutical$RCKT Rocket Pharmaceuticals$RCUS Arcus Biosciences, Inc.$REPL Replimune Group$RGNX REGENXBIO$RIGL Rigel Pharmaceuticals$RLAY Relay Therapeutics$RNXT RenovoRx$RVMD Revolution Medicines, Inc.$RXRX Recursion Pharmaceuticals, Inc.$RZLT Rezolute$SANA Sana Biotechnology$SCTX Scribe Therapeutics$SCYX SCYNEXIS$SENS Senseonics Holdings$SGMT Sagimet Biosciences$SLN Silence Therapeutics$SLS SELLAS Life Sciences$SMMT Summit Therapeutics$SNDX Syndax Pharmaceuticals$SPRO Spero Therapeutics$SRPT Sarepta Therapeutics$SRRK Scholar Rock$STIM Neuronetics$STOK Stoke Therapeutics$SVRA Savara$SYRE Spyre Therapeutics$TAK Takeda Pharmaceutical Company Limited$TARA Protara Therapeutics$TENX Tenax Therapeutics$TGTX TG Therapeutics$TLX Telix Pharmaceuticals$TNGX Tango Therapeutics$TRAW Traws Pharma$TRAX First Tracks Biotherapeutics$TRDA Entrada Therapeutics$TVTX Travere Therapeutics$TYRA Tyra Biosciences$UNCY Unicycive Therapeutics$URGN UroGen Pharma$VCEL Vericel Corporation$VCRE Vicore Pharma$VERA Vera Therapeutics$VIR Vir Biotechnology$VKTX Viking Therapeutics$VNDA Vanda Pharmaceuticals$VOR Vor Biopharma Inc.$VRCA Verrica Pharmaceuticals$VRDN Viridian Therapeutics$VRTX Vertex Pharmaceuticals$VSTM Verastem Oncology$VTGN Vistagen Therapeutics$VTRS Viatris$VTVT vTv Therapeutics$WORX SCWorx Corp.$XBIO Xenetic Biosciences$XENE Xenon Pharmaceuticals$XERS Xeris Biopharma$XNCR Xencor, Inc.$XRTX XORTX Therapeutics$ZBIO Zenas BioPharma$ZLAB Zai Lab$ZNTL Zentalis Pharmaceuticals$ZURA Zura Bio$ZVRA Zevra Therapeutics$ZYME Zymeworks

Why this hub exists

Biotech is one of the few equity sectors where a single company update can completely change the market narrative in one session. A trial readout, an FDA decision, a safety signal, a financing, a regulatory delay, a partnership, or even a conference abstract can move a stock far more than ordinary quarterly numbers.

This hub is designed as a clean starting point for readers who want to follow biotech stocks with a catalyst-first mindset. The goal is not to chase every press release, but to organize the sector around what actually matters for traders: clinical-stage risk, cash runway, dilution pressure, regulatory milestones, institutional positioning, insider behavior, market sentiment, and the difference between a real inflection point and a temporary headline spike.

Core focusEvent-driven biotech
Main risksData, FDA, cash
Reader useResearch map
StyleEducational only

How to read a biotech setup

A biotech stock is rarely just a chart. The chart matters, but the real driver is usually a chain of questions: what asset is being developed, what disease is being targeted, what stage the program is in, how strong the prior data looked, how much cash the company has, how soon the next milestone arrives, and how the market is currently pricing the probability of success.

1. The asset

Start with the drug, device, platform or therapy. What is it supposed to do, what pathway does it target, and why could it matter clinically?

2. The indication

A rare disease, oncology, neurology or cardiometabolic program can carry very different timelines, endpoints, competitive intensity and regulatory paths.

3. The catalyst

Identify the actual event: topline data, PDUFA, advisory committee, abstract, conference presentation, trial initiation, enrollment completion or regulatory filing.

4. The balance sheet

Cash runway and dilution risk matter. Positive data can be powerful, but weak financing conditions can cap the upside or trigger a capital raise.

Biotech categories we track

The hub organizes Merlintrader biotech coverage by catalyst type and clinical theme. This keeps the reader from treating every ticker as the same kind of trade.

FDA / PDUFA names

Companies approaching FDA action dates, regulatory submissions, label decisions, complete response letter recovery paths or advisory committee events.

PDUFAFDAAdCom

Clinical readout names

Small and mid-cap stocks with pending Phase 1, Phase 2 or Phase 3 data where efficacy, safety or durability can reset valuation.

Phase 1Phase 2Phase 3

Commercial launch stories

Biotechs moving from approval to execution, where prescriptions, payer coverage, physician adoption and guidance become the main story.

LaunchRevenueGuidance

Platform stories

Gene editing, RNA, cell therapy, radiopharma, immunology and next-generation modalities where one program may validate a broader technology stack.

PlatformPipelineValidation

Research checklist for any biotech catalyst

This is the practical filter used across Merlintrader biotech coverage. A stock can look exciting on social media, but sound research separates the real catalyst from the noise.

01

Confirm the exact catalyst

Vague phrases like “data soon” say little. A useful catalyst entry identifies the type of event, expected window, trial name, indication and whether the timing is company-guided or only market speculation.

02

Read the trial design

Endpoints, population size, control arm, follow-up duration and prior data quality matter more than the headline alone.

03

Check cash and dilution

A biotech with a short runway may use strength to raise capital. That does not automatically kill a thesis, but it must be part of the setup.

04

Map institutional and insider behavior

Ownership changes, insider buying or selling, and recent financings help frame market confidence, but they should not replace clinical analysis.

05

Separate upside scenario from probability

A huge addressable market does not equal a high-probability trade. The question is what the market already discounts and what new evidence can change.

More Merlintrader biotech research

Use these links to move from this sector hub into deeper research, live catalyst tracking and related educational material.

What makes biotech different from ordinary stock research

Biotech research is not simply a question of revenue, margins and guidance. Many companies in this sector have no commercial revenue at all, or only limited early revenue, while the market value is built around future medical, regulatory and strategic possibilities. That makes the sector fascinating, but also dangerous. A company can look expensive on traditional financial metrics and still be underpriced if a late-stage asset works. Another company can look statistically cheap and still be a value trap if its lead program fails, if the FDA asks for another trial, or if the balance sheet forces a painful financing.

The best way to approach biotech is to think in layers. The first layer is the science: mechanism of action, disease biology, endpoint relevance, prior clinical evidence and safety profile. The second layer is the regulatory path: FDA division, trial design, accelerated approval possibility, advisory committee risk, labeling questions and post-approval commitments. The third layer is the market structure: competing therapies, standard of care, physician behavior, reimbursement, pricing and commercial execution. The final layer is the stock itself: liquidity, float, short interest, institutional sponsorship, insider behavior, retail attention and how much of the story is already priced in.

This hub is built around that layered approach. The purpose is to help readers slow down, organize the facts and avoid treating every biotech headline as if it had the same quality. A Phase 1 safety update is not the same as a Phase 3 primary endpoint readout. A conference abstract is not the same as a peer-reviewed publication. A granted patent is not the same as regulatory approval. A partnership discussion is not the same as a funded collaboration. Those distinctions are often where traders either protect themselves or get trapped.

The main biotech catalyst types

Not all catalysts deserve the same weight. Some events can reset valuation immediately; others are useful but mostly confirm that a program is still moving forward. A serious biotech watchlist should rank catalysts by potential market impact, probability, timing clarity and downside risk if the event disappoints.

Topline clinical data

This is usually the most important catalyst for development-stage companies. The market focuses on whether the trial met its primary endpoint, how secondary endpoints behaved, whether safety was clean, and whether the data are strong enough to support the next regulatory or commercial step.

FDA approval decisions

PDUFA dates can create large moves because they convert a development story into a regulatory decision. The key questions are approval, rejection, label breadth, safety warnings, manufacturing issues and whether launch can begin quickly.

Advisory committee events

An AdCom can be a major swing event because outside experts discuss efficacy, safety and risk-benefit in public. The vote matters, but the tone of discussion can matter just as much.

Conference abstracts and presentations

Medical congresses can bring fresh data, longer follow-up, subgroup analysis or competitive context. The market often reacts before the full presentation, especially when abstracts are released ahead of the event.

Financing and strategic transactions

A capital raise, royalty deal, licensing agreement or partnership can extend runway and validate a program, but terms matter. Dilution can be acceptable when it funds a strong catalyst; it can be destructive when it only buys time.

Commercial launch updates

For approved products, the story shifts from clinical risk to execution risk. Prescription trends, payer coverage, inventory dynamics, gross-to-net, sales force productivity and guidance become central.

How Merlintrader separates real biotech momentum from noise

Momentum in biotech can be real, but it can also be manufactured by thin liquidity, social media excitement or recycled headlines. A stock moving sharply does not automatically mean that the fundamental probability has improved. The first question is always: what changed today compared with what the market knew yesterday?

A strong setup normally has at least one of three elements. First, a new and verifiable piece of information: clinical data, regulatory feedback, financing, partnership, publication, trial update or official guidance. Second, a clear calendar reason for attention: an upcoming FDA date, conference presentation, data window or earnings call that can clarify launch execution. Third, an imbalance between attention and information: the market may be discovering a catalyst late, especially in small caps with limited institutional coverage.

A weak setup often looks exciting at first but fails under basic checks. The catalyst is vague. The company has very little cash. The trial is early and uncontrolled. The endpoint is exploratory. The same news was already announced months earlier. Management language is promotional but not precise. The move is driven by message-board speculation rather than a filing or official source. In those cases, the correct job of research is not to kill the story automatically, but to mark the difference between fact, interpretation and hype.

Featured biotech research areas for this hub

The biotech universe is too large to treat as one bucket. Merlintrader coverage will prioritize names where the catalyst is visible, the market reaction can be meaningful, and the story can be explained clearly to readers. The focus is not only on the biggest companies. Small and mid-cap biotech often produces the most asymmetric moves, but it also demands stricter risk control.

FDA

Regulatory decision stocks

Companies approaching PDUFA dates, FDA resubmissions, label expansion decisions, advisory committees or complete response letter recovery attempts. These names require a precise review of prior data, regulatory history, manufacturing risk and label expectations.

DATA

Clinical readout stocks

Companies with upcoming Phase 1, Phase 2 or Phase 3 data. A complete assessment covers trial design, patient population, endpoint hierarchy, statistical powering, prior studies, safety signals and what would count as a clearly positive or clearly negative result.

RARE

Rare disease companies

Rare disease biotech can move strongly because small patient populations may still support attractive economics, especially when disease burden is high and competition is limited. However, trial size, endpoint choice and regulatory flexibility must be examined carefully.

ONC

Oncology and hematology

Oncology readouts often require more nuance than a headline response rate. Durability, complete responses, progression-free survival, overall survival, safety, line of therapy and competing datasets all matter.

CNS

Neurology and psychiatry

CNS programs can be extremely valuable but difficult to interpret. Placebo response, subjective endpoints, trial design, patient selection and safety tolerability often determine whether a headline result is truly investable.

COMM

Commercial-stage biotech

Once a drug is approved, the market wants evidence that physicians prescribe it, payers cover it, patients stay on therapy and management can scale revenue without destroying margins.

The Merlintrader RunUP Biotech strategy

Merlintrader approaches biotech not only as a sector of medical innovation, but also as one of the market’s most powerful event-driven trading arenas. The core idea behind RunUP Biotech is the phase in which attention, volume, speculation and institutional positioning can build before a known clinical or regulatory catalyst. This is not the same as betting blindly through binary data. In many cases, the more disciplined opportunity lies not in the event itself, but in the market behavior that develops before it.

A run-up begins when a catalyst becomes visible enough to attract attention, but not yet fully digested by the market. The best setups often combine a defined calendar window, a credible scientific or regulatory reason for interest, a stock that has not already priced perfection, and improving market awareness. The move can be driven by anticipation rather than confirmation. That is why the work begins before the headline, not after it.

The Merlintrader approach is built around one simple principle: respect the catalyst, but do not worship it. A catalyst can create opportunity, but it can also destroy capital. The purpose of the run-up strategy is to identify when the market is starting to care, understand why it is starting to care, and evaluate whether the risk/reward still makes sense before the binary moment arrives.

We track the calendar

FDA dates, clinical data windows, congress presentations, earnings calls, trial completion dates and regulatory submissions create the structure of the trade. Without timing, there is no run-up map.

We study the story

The catalyst must have a reason to matter. A stock can have a date on the calendar, but if the asset is weak, the trial is unclear or the market opportunity is limited, the run-up may be fragile.

We watch the tape

Volume expansion, higher lows, improving liquidity, better news response and stronger sector context can confirm that attention is building. A catalyst with no tape support may stay invisible.

We manage the binary risk

The event itself can be dangerous. Holding through data or FDA decisions is a separate decision from trading the anticipation phase. That distinction is central to the Merlintrader style.

Run-up does not mean “buy before news and hope”

A proper biotech run-up strategy is not hype. It is not a social media chase. It is not buying a ticker simply because someone says “data soon.” A real run-up framework starts with evidence and ends with risk control. The question is not whether a company sounds exciting. The question is whether the market has a reason to reprice the stock before the catalyst, and whether the current price still leaves room for that repricing.

The cleanest run-up setups usually have several pieces working together. First, there is a known or strongly guided catalyst window. Second, the program has enough prior evidence to make investor attention rational. Third, the stock has not already completed the entire move. Fourth, the balance sheet is not so weak that every rally becomes an immediate financing opportunity. Fifth, the broader biotech tape is not completely hostile. None of these factors guarantees success, but together they create a better research foundation.

The weakest setups are the opposite. The catalyst is vague, the source is not official, the company needs cash immediately, prior data are thin, the stock has already exploded, and traders are mostly repeating each other. Those can still move, but they do not deserve confident language. They are speculative, fragile and high-risk.

The phases of a biotech run-up

One of the biggest mistakes in biotech trading is treating the whole move as one event. In reality, a run-up often develops in phases. Understanding the phase helps the reader judge how mature a move is and avoid mistaking exhaustion for early momentum.

1

Discovery phase

The catalyst exists, but only a small part of the market is paying attention. Volume is still normal or only slightly above normal. This phase is research-heavy because the edge comes from understanding the calendar before it becomes obvious.

2

Awareness phase

The stock starts appearing on watchlists. Volume improves, social attention rises, and the story begins to circulate. Good reports can help readers understand whether the attention is justified or just noise.

3

Acceleration phase

The market starts pricing the catalyst more aggressively. This is often the fastest part of the move, but also where risk increases quickly because late buyers often enter without understanding the underlying event.

4

Decision phase

The trader must decide whether the run-up trade is over, whether partial de-risking makes sense, or whether holding through the binary event is justified. This is a risk decision, not an emotional decision.

5

Aftermath phase

After data or FDA action, the story changes. A successful catalyst becomes a new valuation exercise. A failed catalyst becomes a damage-control exercise. Either way, the run-up phase is finished.

What readers should take away

The objective is not to turn readers into blind biotech gamblers. The objective is to teach them how to read the setup. A good reader should leave Merlintrader understanding what the catalyst is, why it matters, what can go right, what can go wrong, where the uncertainty sits, and why the stock is moving now.

That is why useful biotech coverage goes beyond a standard market note. A one-line headline can tell readers that a company has data coming. It cannot explain the disease, the endpoint, the prior evidence, the financing risk, the competitive landscape, the retail narrative, institutional ownership, the insider record, the scenario tree or the difference between trading the run-up and holding through the event. That deeper context is where Merlintrader can be useful.

Understand the catalyst

A catalyst should be understandable to a non-specialist without being dumbed down.

Understand the timing

The reader should know whether the event is days away, weeks away, quarter-guided or still uncertain.

Understand the risk

No catalyst is free money. Biotech risk must be explained clearly and directly.

Understand the trade structure

The reader should understand the difference between anticipation, confirmation and binary-event exposure.

What can break a run-up

A run-up can fail even before the main catalyst arrives. This is why the failure modes deserve equal attention. The most common problem is dilution. If a company has limited cash and the stock rallies, management may raise money before the catalyst. Sometimes that is rational and even necessary, but it can still hurt traders who entered late. Another problem is timing slippage. A catalyst expected in one quarter may move into the next one, and momentum can fade quickly when the calendar becomes less urgent.

There is also the problem of overpricing. A stock that doubles or triples before data may leave very little room for disappointment. Even positive data can sell off if the market expected perfection. Competitive read-throughs can also hurt: a rival dataset, FDA comment, safety issue or commercial update can change the perceived value of a program before the company reports anything new.

The final risk is narrative exhaustion. In small-cap biotech, attention can be temporary. When volume dries up, the same story that looked powerful during the acceleration phase can suddenly feel abandoned. The quality of the science must therefore be separated from the quality of the trade setup. They are connected, but they are not identical.

What a Merlintrader biotech deep dive covers

Each Merlintrader biotech ticker page is designed so a reader can understand the full story without opening ten tabs. The analysis moves from simple to complex: first the company, then the asset, then the catalyst, then the financial and market context.

Executive summary

A plain-English overview of what the company does, why the stock matters now, what the next catalyst is and what the biggest risk is.

Company background

History, corporate strategy, pipeline, lead asset, therapeutic area, management profile and how the current story developed.

Clinical and regulatory review

Trial names, phases, endpoints, prior data, FDA interactions, expected timeline and what investors should watch in the next update.

Financial snapshot

Cash, debt, burn rate, runway, recent offerings, ATM facilities, warrants and the likelihood that the company may need capital.

Ownership and market behavior

Institutional holders, insider activity, short interest, float dynamics, volume changes and retail attention.

Scenario analysis

Bull, base and bear cases written clearly, without pretending that uncertain outcomes are guaranteed.

Important risk note

Biotech can move violently in both directions. Positive trial results can trigger large upside gaps, but failed endpoints, safety concerns, FDA delays, complete response letters, weak launches, dilution, debt pressure or strategic uncertainty can create severe losses. This hub is built for research and education, not for buy or sell recommendations.

Next biotech research stop

Start with the calendar, then move into the deep dives. The best biotech reports usually begin with the event window, then work backward into science, cash, valuation and market expectations.

Biotech Catalyst Calendar 2026

What a Merlintrader deep dive includes

  • Company story: what the company actually does.
  • Lead asset: mechanism, indication and clinical stage.
  • Catalyst map: exact milestone and expected timing.
  • Financial snapshot: cash, burn, runway and dilution risk.
  • Ownership: insiders, institutions and recent changes.
  • Scenarios: bull, base and bear case.

Get these reports in real time

Join the Merlintrader Telegram channel and receive every new deep dive and market update the moment it goes live.

Join @merlintraderpub_com on Telegram

Educational disclaimer. This page is for informational and educational purposes only and does not constitute financial advice, investment advice, medical advice, a solicitation, or a recommendation to buy or sell any security. Biotech equities are high-risk and can be extremely volatile around clinical, regulatory and financing events. Always conduct independent research and consult a qualified professional before making financial decisions.

Disclaimer. The reports in this library are published by Merlintrader for educational and informational purposes only. They are independent journalism and research, dated to the day printed on each report. They do not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and they are not research reports within the meaning of applicable United States securities regulation.

Figures come from public filings, company releases, official trial registries and regulatory documents, stated with their reference dates. They become outdated as new filings and events occur: verify every figure against the primary source and the current stock hub before relying on it. Small and mid-cap and biotechnology stocks can be extremely volatile and may result in partial or total loss of capital. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.

Reports are for personal use only. Redistribution is prohibited. Full legal information is available on the disclaimer and terms of use and privacy pages.